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ABSTRACT 
 
China has among the lowest incidence of type 1 diabetes (T1D) globally, but this incidence is 
rising T1D in China, complicated by multiple barriers including deficits in knowledge and 
motivation surrounding self-monitoring of blood glucose, fixed insulin regimen, limited time with 
physicians, and stigma, makes self-management difficult. Within this challenging context, T1D is 
poorly controlled in Beijing. This study aimed to evaluate a new clinical consultation protocol, 
which incorporated problem solving skills training, goal setting, and nutrition education delivered 
through a framework of motivational interviewing, for patients with T1D at the Peking University 
People’s Hospital in Beijing, China. From October 2017 through March 2018, 40 patients were 
recruited, with 23 completing follow up surveys 70.6±41.1 days later. Changes in patient 
satisfaction, diabetes self-management skill, and intention and motivation to self manage before 
and after receiving the new consultation were calculated. The study sample had a mean age of 
41.7±16.1 years and mean T1D duration of 8.5±9.0 years, and was 55% female (n=22), 79% 
urban (n=31), and 62.5% college educated or higher (n=25). Average HbA1c was 9.9±2.3%, 
demonstrating poor glycemic control. A matched pair analysis demonstrated a significant 
increase of 8.2 (95% CI 3.9-12.4) in diabetes self-management skill score (n=20, p<0.001), and 
an increase of 1.2 (0.6-1.8) in motivation (n=19, p=0.028). A significant change in patient 
satisfaction score (p=0.796) and intention to self manage (0.329) was not demonstrated. We 
conclude that undergoing this new consultation improved patient self-management skill and 
motivation to self-manage, but did not improve patient satisfaction and intention to self-manage. 
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CHAPTER ONE 
INTRODUCTION AND STUDY AIMS 
 
Type 1 diabetes (T1D) is a chronic disease precipitated by the autoimmune destruction of beta-
islet cells of the pancreas, resulting in the decline and eventual complete loss of endogenous 
insulin secretion. Without sufficient insulin secretion, glucose metabolism is disrupted and the 
ensuing hyperglycemia can lead to microvascular symptoms in the short term, and 
macrovascular complications after prolonged poor glycemic control. Appropriate self-
management of TID is critical in achieving glucose homeostasis, preventing long-term 
complications, and ultimately improving health outcomes. However, diabetes self-management 
is no easy task. Diabetes self-management poses a constant consideration that permeates all 
aspects of a patient’s lifestyle and health behaviors. Frequent blood glucose self-monitoring, 
medication adherence, nutrition and diet considerations, and physical activity upkeep are all 
necessary components of proper self-management.1 With incidence trends of T1D on the rise 
globally2,3, there is a pressing need for proper diabetes self-management. Though challenging, 
diabetes self-management and diabetes outcomes are improved when patients enjoy increased 
social support 4-6, and physicians can play a role by contributing to this social support alongside 
behavior change guidance, informational support, and counseling. 
 
The international Diabetes Federation (IDF) estimates the global prevalence of diabetes 2017 to 
be 425 million, with the Western Pacific region accounting for 158 million cases and therefore 
the highest proportion of T1D cases amongst all IDF regions. 7 This worldwide prevalence is 
expected to increase to 629 million by 2045, with China containing the largest population of T1D 
patients within the Western Pacific Region.7 
 
 2 
Global T1D epidemiology has also been described by large registry studies. The World Health 
Organization’s Multinational Project for Childhood Diabetes (WHO DIAMOND Study) collected 
data from 57 countries, identifying 43,013 cases of T1D, with a greater than 350-fold variation in 
incidence of childhood T1D among the 100 populations surveyed. Lower incidence was 
generally seen in South America and China, while higher incidence was seen in Europe as well 
as Canada and New Zealand. China represented the country with the fifth lowest incidence, and 
Beijing specifically was found to have an incidence of 0.9/100,000 per year.8,9 The EURODIAB 
study, collecting incidence data across most countries in Europe as well as Israel from 1989 to 
1994, found a range of incidence of 3.2 to 40.2 cases/100,000 per year,10 and a follow-up study 
from 1989 to 2003 found an annual rate of increase of 3.9%.11 The SEARCH for Diabetes in 
Youth study (2002 to 2012) in the United States reported a T1D incidence over 2002 to 2003 of 
19.5 cases/100,000 youths per year, and a T1D incidence over 2011 to 2012 of 21.7 
cases/100,000 youths per year, showing a significant upward trend.12 
 
A more recent study conducted from 2010 to 2013 estimated an incidence of T1D across all age 
groups in China to be 1.01 per 100,000 person years (0.18 to 1.84) and in Beijing to be 2.46 per 
100,000 person years (2.16 to 2.79).13 Though incidence of type 1 diabetes in China remains 
low relative to global values, incidence is increasing. Compared to the DIAMOND Study’s 
findings, this study estimated a 3.8-fold increase in incidence of children aged 0-14 years over 
an approximately 30 year period.13 Other studies have demonstrated rising incidence of T1D in 
China as well.14,15 The incidence of T1D in Beijing specifically is also rising, with 48% of patients 
having been diagnosed for fewer than 6 years.16 
 
In addition to rising incidence, glycemic control among T1D patients in Beijing is poor, with a 
mean hemoglobin A1c (HbA1c) of 8.3%, and with approximately 1 in 10 patients experiencing 
an episode of severe hypoglycemia and nearly 1 in 4 patients being hospitalized due to diabetic 
 3 
ketoacidosis (DKA) over a one-year period.16 Furthermore, more than one-third of patients 
surveyed presented with DKA at the time of their diagnosis,16 indicating that their diabetes was 
already out of control prior to learning that they have T1D. 
 
When considering the clinical implications of T1D, the lack of endogenous insulin production 
that characterizes this disease is highly disruptive to the body’s ability to clear serum glucose. 17 
Typically, post-prandial elevation of serum glucose is sensed in the pancreas, triggering the 
increased secretion of insulin into portal circulation.17 Insulin circulates systemically and binds to 
the insulin receptor.18 In response, the insulin receptor triggers a phosphorylation cascade using 
its tyrosine-kinase activity.18 This cascade ends with the phosphorylation of Akt, which promotes 
the migration of GLUT 4 glucose transporters to the cell surface to heighten the rate of serum 
glucose clearance.18 In the case of individuals with T1D, however, the inability to secrete 
sufficient insulin and eventual insulinopenia—or complete cessation of endogenous insulin 
production—leaves the patient dependent on exogenous insulin to exert glycemic control and 
survive. 18 
 
The predominant clinical feature of diabetes is chronic hyperglycemia, which can be diagnosed 
by measuring HbA1c levels, fasting plasma glucose (FPG) an oral glucose tolerance test 
(OGTT), or random plasma glucose. 19 These diagnostic criteria are quantified as follows; an 
HbA1c level of 6.5% or greater; a FPG of 126mg/dL or greater; a two-hour plasma glucose of 
200mg/dL or greater following an OGTT; or, in patients exhibiting classic symptoms of 
hyperglycemia or hyperglycemic crisis, a random plasma glucose of 200mg/dL or greater. 19 
However, in T1D, due to rapid onset of symptoms, FPG and OGTT are preferred over HbA1c, 
which reflects long-term glycemic control over a three-month period. Moderately elevated blood 
glucose that does not reach the threshold for diagnosis with diabetes remains concerning. An 
HbA1c of 5.7-6.4%, a FPG of 100-125mg/dL, or a two-hour plasma glucose following an OGTT 
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of 140-199mg/dL indicate an increased risk for the future development of diabetes, and this 
category of moderately elevated blood glucose is referred to as pre-diabetes.19 
 
Acute symptomology of T1D is classically characterized by polydipsia, polyphagia, and polyuria. 
19 These symptoms combined with hyperglycemia represent the diagnostic hallmarks of T1D in 
children and adolescents. 19 If left poorly controlled, T1D can result in long-term complications 
as well at both the micro- and macrovascular levels. The former level includes nephropathy, 
retinopathy, and neuropathy, while the latter involves cardiovascular disease, cerebrovascular 
disease, and peripheral vascular disease. 17 
 
Insulin is a golden standard for treatment of T1D and can be administered in one of two ways. 
The first approach involves carbohydrate counting and administering the appropriate dose of 
insulin in response.20,21 This method is more flexible to the dietary preferences of the T1D 
patient.20,21 The second approach, used in China, involves a more restrictive method of adhering 
to a fixed daily regimen of insulin to which the patient’s diet is matched.22,23 
 
Effective patient-provider interactions are critical to fostering proper self-management of T1D, 
which in turn is necessary to improve diabetes health outcomes. Meanwhile, the status of 
diabetes care delivery in Beijing remains subpar relative to patient outcomes, with nearly 90% of 
respondents having received less than one hour of diabetes education within three months of 
their diagnosis and 60% of respondents indicating that they had not received any diabetes 
education over a one year period.16 Of those who had received diabetes education, just over 
half received it from a physician.16 Additionally, nearly three-fourths of respondents reported that 
they sought emotional support from health care professionals, with almost all (95.9%) finding 
such support helpful in managing their diabetes.16 With approximately 1 in 5 patients in Beijing 
reporting that they have no one to offer them emotional support, it is clear that the patient-
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provider interaction represents a significant opportunity to offer informational and emotional 
support to T1D patients in Beijing.16 However, the potential of the patient-provider interaction to 
offer this support is hindered by the physicians’ extremely limited time.16 Of 39 surveyed 
Chinese physicians, 27 reported exhaustion from their high patient volume.16 Specialists 
additionally reported being placed in non-specialty areas, reducing their time to deliver diabetes-
specific care.16 
 
Previous research has demonstrated the capacity of motivational interviewing (MI) to 
improve patient satisfaction,24-28 advance diabetes health outcomes, 29-31 and promote behavior 
change in both diabetic populations—to improve HbA1c levels among adolescents32 and 
increase intent to self-manage24—and non-diabetic contexts.33-35 Problem-solving skills training 
(PSST) is another intervention that has been shown to successfully elicit behavior change 
among T1D patients to increase blood glucose testing frequency36; improve anxiety, stress, and 
coping37; promote self-efficacy38; and improve quality of life39. However, these interventions 
have largely been enacted outside of the clinical setting, are time- and resource-intensive, and 
require lengthy consultations and frequent follow-up. There is a critical need to understand how 
these proven behavior-change techniques can be applied as a singular consultation protocol 
during typical, brief clinical interactions in order to advance the status of health care delivery to 
patients with T1D. 
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STUDY QUESTIONS AND AIMS 
 
This project aimed to employ standard quantitative data collection methods to address the 
following research questions: 
Question 1: Does a holistic clinical consultation model that employs motivational 
interviewing (MI), goal setting, problem-solving skills training (PSST), and nutrition 
education influence the primary outcomes of laboratory measurements, including 
HbA1c? 
 
Question 2: Does this consultation approach influence patient satisfaction, diabetes self-
management ability, and intention and motivation to self-manage? 
 
To address these questions, the research study will follow one central aim as described below: 
 
Aim 1: To investigate the effectiveness of a new, multifaceted type-1 diabetes 
consultation model involving MI, goal-setting, and PSST during typical, brief clinical 
consultations on clinical and psychosocial patient outcomes. 
Data collection occurred in the Diabetes Clinic at the Peking University People’s Hospital 
(PKUPH) through electronic and paper surveys administered prior to each consultation. 
 
For Aim 1, there were two hypotheses: 
Hypothesis 1: The new consultation protocol will be associated with a decrease in 
HbA1c levels. Additional clinically measurable outcomes will also be explored. 
 
Hypothesis 2: The new consultation protocol will be associated with higher patient 
satisfaction with their clinical experience, increased patient intent and motivation to self-
manage, and improved diabetes self-management.  
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CHAPTER TWO 
 
LITERATURE REVIEW 
 
Overview of Type 1 Diabetes 
Type 1 diabetes (T1D) is a chronic disease precipitated by the autoimmune destruction of beta-
islet cells of the pancreas, resulting in the decline and eventual complete loss of endogenous 
insulin secretion. Without sufficient insulin secretion, glucose metabolism is disrupted and the 
ensuing hyperglycemia can lead to microvascular symptoms in the short term, and 
macrovascular complications after prolonged poor glycemic control. Appropriate self-
management of TID is critical in achieving glucose homeostasis, preventing long-term 
complications, and ultimately improving health outcomes. However, diabetes self-management 
is no easy task. Diabetes self-management poses a constant consideration that permeates all 
aspects of a patient’s lifestyle and health behaviors. Frequent blood glucose self-monitoring, 
medication adherence, nutrition and diet considerations, and physical activity upkeep are all 
necessary components of proper self-management.1 With incidence trends of T1D on the rise 
globally2,3, there is a pressing need for proper diabetes self-management. Though challenging, 
diabetes self-management and diabetes outcomes are improved when patients enjoy increased 
social support 4-6, and physicians can play a role by contributing to this social support alongside 
behavior change guidance, informational support, and counseling. 
 
Environmental Determinants 
T1D is believed to be caused by the interaction of several environmental determinants with an 
individual’s genetics, though the literature is mixed and unable to identify any absolute 
environmental causes. Gestational events such as pre-eclampsia, congenital rubella exposure, 
and blood type incompatibility, as well as high birth weight and being born large for gestational 
age, may each confer risk for development of T1D. 40 Dietary patterns that emphasize dairy milk 
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and wheat gluten were found to be associated with increased risk of T1D, while breastfeeding 
and increased vitamin D consumption were associated with a decreased risk.41 Enterovirus, 
rotavirus, and cytomegalovirus infection can activate T1D-autoimmune activity and beta-cell 
damage.42,43 Drugs identified as toxic to the beta cells include alloxan and streptozotocin, as 
well as the antibiotic drugs pentamidine, vancomycin, and neomycin.44-46 Organochlorine 
pollutants including dioxins, the pesticide DDT, and polychlorinated biphenyls, as well as air 
pollutants can cause T1D.47-50. Composition of gut microbiota has been studied extensively and 
found to be associated with the development of T1D.51 Stress has also been found to increase 
T1D-related autoimmune activity and beta-cell stress.52 
 
Global and Chinese Epidemiology 
Type 1 diabetes is an emerging epidemic on the global scale.53 The international Diabetes 
Federation (IDF) estimates the global prevalence of diabetes 2017 to be 425 million, a figure 
that is expected to increase to 629 million by 2045.7 The Western Pacific region accounts for the 
highest proportion of diabetes cases amongst all IDF regions with 158 million cases.7 Within the 
Western Pacific region, China containing the largest population of diabetes patients.7 The 
proportion of diabetes cases that are T1D cases in high-income countries is estimated to be 7-
12%; this proportion was not available for middle- and low-income countries.7 The proportion of 
diabetes cases represented by T1D for China is estimated to be under 5%.54 The IDF reports 
the total number of T1D cases in children and adolescents younger than twenty years to be 
1,106,200 with 132,600 new cases annually. 7 Between the IDF regions, the Western Pacific 
had the second lowest number of childhood and adolescent T1D cases at 110,000 cases. 7 
Within the Western Pacific region, China was reported to have the fourth highest population of 
children and adolescents younger than twenty years with T1D at 47,000 as well as the fourth 
highest number of new childhood and adolescent T1D cases at 6000 cases per year.7 One 
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study estimates the prevalence of total diagnosed and undiagnosed diabetes in China to be 
10.9%, and that of pre-diabetes to be 35.7%.54 
 
T1D has been described on a global scale by large registry studies, and T1D trends have been 
described most extensively in the United States and European countries. The EURODIAB study 
collected incidence data from 44 different centers across most countries in Europe as well as 
Israel over the period 1989 to 1994. This study found a range of 3.2 to 40.2 cases/100,000 per 
year. The average annual rate of increase in incidence was 3.4%. 10 This rate of increase was 
updated to 3.9% by a follow-up study that covered the years 1989-2003 and focused on 20 
registers across 17 European countries. 11 The SEARCH for Diabetes in Youth study, 
conducted in five clinical sites from 2002 to 2012, 11,245 youths with T1D were identified over 
54,239,600 person-years. T1D incidence in 2002-2003 was 19.5 cases/100,000 youths per 
year, while that in 2011-2012 was 21.7 cases/100,000 youths per year, showing a 1.4% annual 
increase in T1D incidence rates. 12 
 
The World Health Organization’s Multinational Project for Childhood Diabetes (WHO DIAMOND 
Study) collected data from 114 populations 112 centers in 57 countries to describe global T1D 
incidence from 1990 to 1994. Among the study population of 84 million children, a total of 
43,013 cases of T1D were diagnosed. This study identified a greater than 350-fold variation in 
incidence of childhood T1D among the 100 populations surveyed, with Zunyi, China showing 
the lowest incidence at 0.1/100,000 children per year and Finland having the highest incidence 
at 40.9/100,000 per year. Lower incidence was generally seen in South America and China, 
while higher incidence was seen in Europe as well as Canada and New Zealand. China 
represented the country with the fifth lowest incidence, and Beijing specifically was found to 
have an incidence of 0.9/100,000 per year.8,9 
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A more recent study conducted from 2010 to 2013 estimated an incidence of T1D across all age 
groups in China to be 1.01 per 100,000 person years (0.18 to 1.84) and in Beijing to be 2.46 per 
100,000 person years (2.16 to 2.79).13 Though T1D incidence in China remains low, incidence 
is increasing. One study performed in Harbin, China from 1990-2000 reported increasing 
incidence in children aged 0-14,14 and another study conducted in Shanghai, China from 1997-
2011 also reported increased incidence of T1D.15 Compared to the DIAMOND Study’s incidence 
estimate of 0.51 and 0.59 per 100,000 person years among patients younger than 15 years in 
1985-94 and 1988-96, respectively, this study estimated an under-15 year old incidence of 1.93 
per 100,000 person years, indicating a 3.8-fold increase in incidence of children aged 0-14 
years over a nearly 30 year period.13 Table 1 further describes this study’s findings. The 
incidence of T1D in Beijing is also rising, with 48% of patients having been diagnosed for fewer 
than 6 years according to the 2011-2012 3C Study of Coverage, Cost, and Care.16 
 
Table 2.1: Incidence of Type 1 Diabetes in China by Age Group, 2010-2013.13 
Age Group Incidence (95% CI) per 100,000 person years 
0 to 14 years 1.93 (0.83 to 3.03) 
15 to 29 years 1.28 (0.45 to 2.11) 
30 years and older 0.69 (0.00 to 1.51) 
All Ages 1.01 (0.18 to 1.84) 
 
 
Genetic Causes and Biochemical Implications 
T1D is caused by the actions of these environmental determinants on individuals who are 
genetically susceptible. The result is the autoimmune, cytotoxic T cell-mediated destruction of 
beta-islet cells of the pancreas. 55 Variants of the human leukocyte antigen (HLA) genes, the 
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gene responsible for antigen presentation, have been identified to have strong association with 
T1D. HLA class II genes are especially strongly associated with T1D, accounting for 40-50% of 
the genetic risk.56 Other genes have been linked to T1D as well, such as INS, which is involved 
in proper beta cell function; CTLA4 and FOXP3, both of which play a role in immune tolerance; 
and GAD65, which is involved in auto-reactive T cell response.51 The genetic cause of T1D 
remains complex, with many other genes identified to hold a link as well, including PTPN22, 
IL2RA, IFIH1, CAPSLIL7R, CLEC16A, and PTPN2.57 Aberrant epigenetic modifications in the 
form of DNA methylation, histone acetylation, and miRNA regulation can also yield inheritable 
genetic changes that may cause T1D.51 
 
This lack of endogenous insulin production is highly disruptive to the body’s ability to clear 
serum glucose. Typically, post-prandial elevation of serum glucose triggers the increased 
secretion of insulin. Insulin circulates systemically and binds to the insulin receptor, found 
predominantly among skeletal muscle, cardiac muscle, and adipocytes. In response, the insulin 
receptor sets off a phosphorylation cascade using its tyrosine-kinase activity. This cascade ends 
with the phosphorylation of Akt, which promotes the migration of GLUT 4 glucose transporters 
to the cell surface to heighten the rate of serum glucose clearance.58 In the case of individuals 
with T1D, however, the inability to secrete sufficient insulin and eventual insulinopenia—or 
complete cessation of endogenous insulin production—leaves the patient dependent on 
exogenous insulin to exert glycemic control and survive.  
 
Acute Symptoms and Diagnosis 
The predominant clinical feature of T1D is chronic hyperglycemia,59 which is measured by 
HbA1c levels, fasting plasma glucose (FPG) an oral glucose tolerance test (OGTT), or random 
plasma glucose. The FPG and OGTT measure blood glucose in the short term. The FPG 
requires at least an eight hour-long overnight fast before serum glucose levels are measured. 
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The OGTT also requires an overnight fast, followed by the oral consumption of 75g of glucose. 
Blood glucose levels are measured at a series of time points following consumption. These 
diagnostic criteria are quantified as follows (Table 2); a FPG of 126mg/dL or greater; a two-hour 
plasma glucose of 200mg/dL or greater following an OGTT; an HbA1c level of 6.5% or greater; 
or, in patients exhibiting classic symptoms of hyperglycemia or hyperglycemic crisis, a random 
plasma glucose of 200mg/dL or greater. Moderately elevated blood glucose that does not reach 
the threshold for diagnosis with diabetes is still concerning. An HbA1c of 5.7-6.4%, a FPG of 
100-125mg/dL, or a two-hour plasma glucose following an OGTT of 140-199mg/dL indicate an 
increased risk for the future development of diabetes. This category of moderately elevated 
blood glucose is referred to as pre-diabetes. 
 
Table 2.2: Diagnostic Criteria for Pre-diabetes and Diabetes. 
 Fasting Plasma 
Glucose (FPG) 
Oral Glucose 
Tolerance Test (OGTT) 
 
HbA1c (%) 
 
Pre-diabetes 100-125 mg/dL 140-199 mg/dL 5.7-6.4% 
Diabetes ≥ 126 mg/dL ≥ 200 mg/dL ≥ 6.5% 
 
Considering that diagnosis depends on the measurement of hyperglycemia in the setting of 
acute onset of classic T1D symptomology, HbA1c is less commonly used since this measure of 
serum glucose accounts for long-term glycemic control over 3 months. Classic, acute T1D 
symptomology includes polydipsia, excessive thirst or excess liquid consumption, polyphagia, 
excessive hunger or increased appetite—especially with unintended weight loss, and polyuria, 
excess urine production or increased urine frequency. Additional symptoms include mood 
changes and irritability, fatigue, and visual changes such as blurred vision.59,60  
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Micro- and Macrovascular Long-Term Complications 
If left poorly controlled untreated, T1D can also result in long-term complications at both the 
micro- and macrovascular levels. The former level includes nephropathy, retinopathy, and 
neuropathy, while the latter involves cardiovascular disease, cerebrovascular disease, and 
peripheral vascular disease. Diabetic nephropathy is cited as the most common cause of renal 
failure among developed countries. Past estimates of T1D patients who develop end-state renal 
disease were as high as 30-40%, though currently these figures are decreasing due to intensive 
intervention efforts. Diabetic nephropathy progresses from subclinical manifestation to the 
earliest observable state of microalbuminuria, when urine albumin excretion is between 20-
200µg. Once urine albumin exceeds 200µg to reach a state of macroalbuminuria, renal 
dysfunction and ultimately end-state renal disease develop. Having diabetes as comorbidity 
complicates renal disease, as patients on dialysis who are also diabetic tend to do worse than 
non-diabetic dialysis patients. 61 Diabetic retinopathy represents the most common cause of 
acquired blindness in the West. Diabetic retinopathy also progresses through typical stages, 
starting with background retinopathy involving microaneurysms, exudates, and hemorrhages. 
This state then progresses to pre-proliferative retinopathy, followed by proliferative retinopathy 
and the associated risk for retinal detachment, macular swelling, and vitreous hemorrhage.62 
The final microvascular condition facing a long-term case of T1D is diabetic neuropathy, either 
focal or generalized. The most prevalent generalized neuropathy is sensorimotor 
polyneuropathy, which most commonly presents as peripheral neuropathy of the distal arms and 
legs, but also affects the autonomic nervous system. Peripheral neuropathy, along with 
peripheral vascular disease, may cause skin ulceration of the lower limbs, with associated slow 
healing and gangrene infection, as well as diabetic foot ulcers that could eventually worsen to 
the point of needing amputation.61 The risk for all of these microvascular complications, 
however, decrease with intensive insulin therapy.63 
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Macrovascular complications include cardiovascular disease such as coronary artery disease, 
angina, atherosclerosis, and hypertension, as well as acute cardiac events such as myocardial 
infarction, and stroke.63 The risk of cardiovascular disease for individuals with T1D can be as 
much as ten times higher than that for non-diabetics.64 Even following an acute cardiac event, 
T1D patients fare worse outcomes than their non-diabetic peers.65 Conventional risk factors for 
macrovascular complications in individuals with T1D include older age, higher HbA1c, male sex, 
status as a smoker, and higher systolic and diastolic blood pressures, higher BMI, higher serum 
triglycerides, higher total cholesterol, lower HDL cholesterol, and higher LDL cholesterol. 66 
 
Treatment and Management 
Management of T1D is a multifaceted activity that demands consideration of diet, medication, 
and lifestyle. At the time of diagnosis, some T1D patients retain the ability to secrete low levels 
of insulin. Therefore, preservation of this minimal level of secretion becomes a major therapeutic 
priority achieved through rigorous insulin treatment, mechanical technologies, and interventions 
targeting the autoimmune activity to prevent further beta cell degradation. 
 
Since its discovery in 1921-1922, exogenous insulin has been a defining factor in the 
management of T1D and can be administered in one of two ways. The first approach involves 
carbohydrate counting, in which the carbohydrate content of food is summed and the 
appropriate dose of insulin is administered in response.20,21 This method is more flexible to the 
dietary preferences and daily lifestyle variations of the T1D patient. The second approach, used 
in China, involves a fixed daily regimen of insulin matched to a diet that is rigid in amount and 
timing.22 Though each individual T1D patient should work with their health care provider in order 
to arrive at the most appropriate insulin regiment, individuals with T1D often perceive this fixed 
pattern of insulin administration as severely restrictive and limiting of their lifestyle choices. 23 It 
is typically held that a flexible insulin dosing schedule is better than a fixed insulin regimen 
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because the former better protects against hypoglycemia associated with variations in eating, 
physical activity, and sleep.67  
 
Clinical Description of Type 1 Diabetes In China 
 According to a cross-sectional study conducted by the IDF among countries in the Western 
Pacific region between 2001-2002, the mean HbA1C in China was 9.5% (Western Pacific 
Region: 8.8%).68 In comparison, individuals with T1D in the United States were found to have a 
mean HbA1c of 7.7%.69 This study also found a hypoglycemia rate of 38.8 events per 100 
patient-years (Western Pacific Region: 74.0 events per 100 patient-years), a DKA rate of 7.1 
events per 100 patient-years (Western Pacific Region: 9.9 events per 100 patient-years), a 
microalbuminuria prevalence of 6.7% (Western Pacific Region: 2.6%), and a hypertension 
prevalence of 23.9% (Western Pacific Region: 21.6%).68 
 
The 3C Study of Coverage, Cost, and Care, a cross-sectional study investigating clinical 
practices and diabetes outcomes from 2011 to 2012, describes characteristics of T1D in Beijing 
specifically.16 The incidence of T1D in Beijing is rising, with 48% of patients having been 
diagnosed for fewer than 6 years. These cases of T1D in Beijing are poorly controlled, with a 
mean HbA1c among T1D patients of 8.3%. Approximately 1 in 10 patients experienced an 
episode of severe hypoglycemia over a one-year period, and nearly 1 in 4 patients were 
hospitalized due to diabetic ketoacidosis over a one-year period. More than one-third of patients 
surveyed presented with DKA at the time of their diagnosis, indicating that their diabetes was 
already out of control prior to learning that they have T1D.  
 
Status of Self-Management in China 
The IDF’s cross-sectional study on diabetes self-management and glycemic control patterns 
from 2001-2002 found that children and adolescents with T1D in China had the lowest mean 
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daily insulin dose and the lowest frequency of self-monitoring of blood glucose (SMBG) among 
nations of the Western Pacific IDF region.68,70 A recent study conducted in 2012 in Guangzhou, 
China—a relatively developed city—utilized the information-motivation-behavior skills model of 
health behavior to investigate T1D self-management patterns. The study identified deficits in 
knowledge surrounding self-management, including the lack of understanding of the interaction 
of exercise (50.9%) and diet (47.3%), the inability to ascertain blood sugar patterns from self-
monitoring data (40.0%), not knowing how often to perform SMBG (18.2%), and not knowing 
how to respond to elevated blood glucose (16.4%). This study also found that patients were 
facing several barriers to feeling motivated to SMBG, including the associated expense (85.5%), 
pain (72.7%), unpleasantness (56.4%), anxiety (56.4%), effects on their ability to perform their 
occupation (54.5%), time intensiveness (52.7%), and interference with daily activities (52.7%).71 
In regards the dietary aspect of diabetes self-management, it has been observed that, while 
individuals with T1D in China are making carbohydrate-conscious decisions in their diets,72 this 
patient population is lacking in carbohydrate counting skills.22 
 
Status of Type 1 Diabetes Care in China 
Effective patient-provider interactions are critical to fostering proper self-management of T1D, 
which in turn is necessary to improve diabetes health outcomes. Meanwhile, the status of 
diabetes care delivery in Beijing remains subpar, with nearly 90% of respondents having 
received less than one hour of diabetes education within three months of their diagnosis and 
60% of respondents indicating that they had not received any diabetes education over a one 
year period. Of those who had received diabetes education, just over half received it from a 
physician. Additionally, nearly three-fourths of respondents reported that they sought emotional 
support from health care professionals, with almost all (95.9%) finding such support helpful in 
managing their diabetes. With approximately 1 in 5 patients in Beijing reporting that they have 
no one to offer them emotional support, it is clear that the patient-provider interaction represents 
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a significant opportunity to offer informational and emotional support to T1D patients in Beijing. 
However, the potential of the patient-provider interaction to offer this support is hindered by the 
physicians’ extremely limited time. Of 39 surveyed Chinese physicians, 27 reported exhaustion 
from their high patient volume. Specialists additionally reported being placed in non-specialty 
areas, reducing their time to deliver diabetes-specific care.16 
 
Another study demonstrated that patients additionally feel ill-equipped to seek medical care, 
with 41.8% of respondents stating that they feel unable to seek care from their doctor for blood 
sugar monitoring, 38.2% of respondents reporting they are unsure of what information from their 
meter to bring to their appointments, and 38.2% of respondents stating that they feel unable to 
speak with their doctor about their blood sugar self-monitoring records even if the doctor does 
not ask.71 
 
Stigma Against Type 1 Diabetes in China 
In 2011, the IDF published a statement declaring the right of individuals with diabetes to be fully 
engaged members of society who are afforded equitable access to all the rights and privileges 
of their peer citizens, including access to health care and appropriate education needed to help 
them manage their diabetes. The IDF also stated that individuals with diabetes should not have 
to hide their diagnosis.73 However, in China, there exists significant stigma associated with 
being diagnosed with T1D, which complicating the status of T1D care delivery and represents a 
social barrier to proper self-management.74 Proposed explanations for this stigma include 
China’s T1D incidence, among the lowest in the world8; being so uncommon, T1D is perceived 
as strange and patients are even seen as ‘monsters’ of society. Public opinion, understanding 
that T1D can be caused by genetic factors, believes T1D to be highly heritable and therefore the 
fault of the individual’s family. The associated stigma even makes an individual with T1D less 
desirable for marriage and less accepted by their own family.74 
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The stigma pervades educational and professional life as well. Individuals with T1D can be 
refused admittance to universities and junior colleges, and discriminated against in the job 
market. 74 It was identified in one study that 63.6% of respondents found it difficult to discuss 
their diabetes with their coworkers, and 52.7% found it difficult to discuss their diabetes with 
their friends.71 Consequently, T1D patients will hide their disease, which can often lead to 
suboptimal diabetes self-management such as non-adherence to insulin dosing, inconsistent or 
absence of blood glucose monitoring, and inappropriate response to hypoglycemic episodes.74 
 
Diabetes Self-Management Education and Counseling Strategies 
Motivation interviewing (MI) is an interviewing technique that promotes patient-centered 
communication and placing the patient as an active participant in their care. Though not an 
intervention itself, MI can bolster the effectiveness of attempts to promote behavior change by 
increasing the patient’s participation in the behavior change techniques and supplying 
motivation to make such changes. MI makes for a collaborative environment in which patients 
are allowed to reason through the necessity for behavior change, understand and resolve their 
hesitation to change, strategize mechanisms to make a change, and develop confidence in their 
ability to handle change.75,76 One presentation of the MI framework emphasizes six key skills, 34 
beginning with sharing the agenda, where patients are given the ability to raise all of their 
concerns and contribute to deciding the central agenda for the consultation. Next is raising the 
issue, which encourages providers to reciprocally bring up issues that they find concerning, 
which is followed by the third skill of expressing respect and empathy. Another skill is to build on 
what is heard, which follows an ask-tell-ask format. Providers are encouraged to truly listen to 
and understand the patient, and build the conversation around the patient’s concerns. The fifth 
component emphasizes the importance of cultivating change talk in order to capitalize on and 
reinforce moments during which the patient expresses their openness to making a change. 
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Finally, the MI framework highlights the need for guidance towards a specific plan to target the 
intended change in a practical and tangible manner. In this way, MI gives weight to how the 
framework through which program content is delivered is just as important as the content itself. 
 
Another major behavior change counseling strategy is problem-solving skills training 
(PSST), which detail procedures for identifying barriers to proper management and formulating 
methods for disrupting them. Management of chronic diseases, such as T1D, is a laborious and 
multifaceted process that is unique to each patient’s individual circumstances, and does not 
entail any singular solution.77 Rather, patients must identify and implement personalized 
strategies to address these individual barriers to proper management, and PSST is the 
framework by which this solution development can take place.78,79 While the patient may have 
the necessary knowledge to self-manage their disease, problem solving helps patients actually 
translate this knowledge into the reality of their lives and implement specific goals to improve 
self-management.80,81 
 
Previous research has demonstrated the capacity of MI to improve patient satisfaction,24-
28 advance diabetes health outcomes, 29-31 and promote behavior change in both diabetic 
populations—to improve HbA1c levels among adolescents32 and increase intent to self-
manage24—and non-diabetic populations.33-35 Problem-solving is another intervention that has 
been shown to successfully elicit behavior change among T1D patients to increase blood 
glucose testing frequency36; improve anxiety, stress, and coping37; promote self-efficacy38; and 
improve quality of life39. However, these interventions have largely been enacted outside of the 
clinical setting, are time-consuming and resource-intensive, and require lengthy consultations 
and frequent follow-up. There is a critical need to understand how these proven behavior-
change techniques can be applied as a singular consultation protocol during typical, brief clinical 
interactions in order to advance the status of health care delivery to patients with T1D.  
 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER THREE 
MANUSCRIPT FOR PUBLICATION   
 21 
ABSTRACT 
China has among the lowest incidence of type 1 diabetes (T1D) globally, but this incidence is 
rising T1D in China, complicated by multiple barriers including deficits in knowledge and 
motivation surrounding self-monitoring of blood glucose, fixed insulin regimen, limited time with 
physicians, and stigma, makes self-management difficult. Within this challenging context, T1D is 
poorly controlled in Beijing. This study aimed to evaluate a new clinical consultation protocol, 
which incorporated problem solving skills training, goal setting, and nutrition education delivered 
through a framework of motivational interviewing, for patients with T1D at the Peking University 
People’s Hospital in Beijing, China. From October 2017 through March 2018, 40 patients were 
recruited, with 23 completing follow up surveys 70.6±41.1 days later. Changes in patient 
satisfaction, diabetes self-management skill, and intention and motivation to self manage before 
and after receiving the new consultation were calculated. The study sample had a mean age of 
41.7±16.1 years and mean T1D duration of 8.5±9.0 years, and was 55% female (n=22), 79% 
urban (n=31), and 62.5% college educated or higher (n=25). Average HbA1c was 9.9±2.3%, 
demonstrating poor glycemic control. A matched pair analysis demonstrated a significant 
increase of 8.2 (95% CI 3.9-12.4) in diabetes self-management skill score (n=20, p<0.001), and 
an increase of 1.2 (0.6-1.8) in motivation (n=19, p=0.028). A significant change in patient 
satisfaction score (p=0.796) and intention to self manage (0.329) was not demonstrated. We 
conclude that undergoing this new consultation improved patient self-management skill and 
motivation to self-manage, but did not improve patient satisfaction and intention to self-manage. 
 
Key Words: Type 1 diabetes, China, self-management, clinical consultation, nutrition  
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INTRODUCTION 
 
China is reported to have among the lowest incidence of type 1 diabetes globally,8,9 but 
incidence rates in China13-15 and Beijing16 are rising. Compared to the WHO DIAMOND Study’s 
outcomes from 1985-94, more recent findings indicated a 3.8-fold increase in incidence among 
patients aged 0-14 years.13 In this context of the growing significance of T1D in China, it is 
important to recognize that several barriers complicate diabetes self-management. Patients with 
T1D in China face deficits in knowledge about self-management and motivation to self-manage, 
71 a fixed insulin regimen that is restrictive to their diets,22 limited time with physicians during 
clinic visits,16 and pervasive stigma against T1D.74 The IDF’s cross-sectional study on diabetes 
self-management and glycemic control patterns from 2001-2002 found that children and 
adolescents with T1D in China had the lowest mean daily insulin dose and the lowest frequency 
of self-monitoring of blood glucose (SMBG) among nations of the Western Pacific IDF 
region.68,70 Therefore, it is understandable that, within this challenging context, these cases of 
T1D in Beijing are poorly controlled. Patients were found to have a mean HbA1c of 8.3%.16 
Approximately 1 in 10 patients experienced an episode of severe hypoglycemia over a one-year 
period, and nearly 1 in 4 patients were hospitalized due to diabetic ketoacidosis (DKA) over a 
one-year period.16 More than one-third of patients presented with DKA at the time of their 
diagnosis,16 indicating that their diabetes was already out of control prior to learning of their 
diagnosis. 
 
Effective patient-provider interactions are critical to fostering proper self-management of T1D, 
which in turn is necessary to improve diabetes health outcomes. In Beijing, nearly 90% of 
survey respondents received less than one hour of diabetes education within three months of 
their diagnosis and 60% of respondents indicated not receiving any diabetes education over a 
one-year period.16 Additionally, nearly three-fourths of respondents reported that they sought 
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emotional support from health care professionals, with almost all (95.9%) finding such support 
helpful in managing their diabetes.16 With approximately 1 in 5 patients in Beijing reporting that 
they have no one to offer them emotional support, it is clear that the patient-provider interaction 
represents a significant opportunity to offer informational and emotional support to T1D patients 
in Beijing. However, this potential source of support is hindered by limited time and physician 
exhaustion.16 At the Peking University People’s Hospital (PKUPH), endocrinologists had mere 
minutes to spend with each patient, and reported seeing 90 to 100 patients daily.  
 
Prior literature has demonstrated the capacity of motivational interviewing (MI) to improve 
patient satisfaction,24-28 advance diabetes health outcomes, 29-31 and promote behavior change 
in diabetic populations to improve HbA1c levels among adolescents32 and increase intent to 
self-manage.24 Problem-solving is another intervention that has been shown to successfully 
elicit behavior change among T1D patients to increase blood glucose testing frequency36; 
improve anxiety, stress, and coping37; promote self-efficacy38; and improve quality of life.39 
However, these interventions have largely been enacted outside of the clinical setting, are time-
consuming and resource-intensive, and require lengthy consultations and frequent follow-up. 
 
It is within this context that a T1D-specific clinic was opened at PKUPH, for which a new clinical 
consultation protocol was developed. This protocol combined the tenets of problem solving, goal 
setting, and nutrition education and used motivational interviewing as the framework for content 
delivery. We conducted an initial program evaluation to assess the effectiveness of this new 
consultation protocol in changing patient satisfaction, self-management skill, and intention and 
motivation to self manage.  
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METHODS 
 
Study Design 
This program evaluation utilizes a pre-post analysis to evaluate differences in patient 
satisfaction with care, diabetes self-management skill, and intention and motivation to self-
manage. The population comprised patients with T1D in Beijing, China who received care at 
PKUPH. Inclusion criteria required participants in the study to be 15 years of age or older, not 
be currently pregnant, and have been diagnosed with T1D by a certified doctorate specialist. 
Case report forms (Appendix A) were developed to assess patient eligibility for the study and 
record their recruitment outcome (Eligibility and Recruitment Outcome Form), to record 
demographic characteristics and baseline clinical data (Demographic and Clinical Data Form), 
and to record clinical data at consultation visits beyond baseline (Clinical Update Form). 
Consent forms were developed to ensure informed consent, including an adult consent form as 
well as parental consent and youth assent forms for minors (Appendix B). The Diabetes 
Interview Satisfaction Survey (DISS),24 the Diabetes Self-Management Questionnaire—Self-
Report (DSMP),82 and the Intention and Motivation Questionnaire82 were adapted for use as 
data collection instruments in this study (Appendix C). All of these documents were translated 
into Mandarin Chinese (WL). These translated versions of the documents can be found with the 
original English version in their respective appendices. This study was reviewed and received 
approval from the Institutional Review Boards of both the University of North Carolina at Chapel 
Hill (June 2017) and Peking University (October 2017). 
 
Consultation Development 
A new clinical consultation protocol (Appendix D) for T1D patients was developed, drawing 
heavily from the integration of Reims and Ernst’s motivational interviewing framework for 
promotion of healthy weight loss34 and protocols for problem solving and goal setting from the 
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Flexible Lifestyle Empowering Change (FLEX) study, a NIH-funded intervention for self-
management in adolescents with T1D in the United States,82 as well as nutrition education and 
carbohydrate counting skills. The consultation protocol was then translated into Mandarin 
Chinese (WL). The consultation protocol described the procedures for the first two visits in the 
series, with the third consultation protocol serving as the outline for all future visits, with an 
anticipated follow up period of one month between visits. Consultations were designed to last 
for 15-20 minutes. 
 
The first consultation was designed to allow the patient to express their concerns, have the 
endocrinologist review nutrition education, and problem solve around one specific concern. The 
consultation starts with raising of the issue, in which the patient is allowed to share all of their 
concerns surrounding their diabetes self-management, without being interrupted by the 
physician at the first concern. The physician allows the patient to convey all of their concerns 
before summarizing them back to the patient in order to both confirm correct understanding and 
convey this understanding to the patient. The physician then negotiates the patient’s concerns 
with their own clinical judgment in order to develop a shared agenda for the visit. Once a 
specific concern is identified as the first item on this agenda, the physician asks a broad 
question, such as “could you tell me what you understand about [concern] and what are you 
currently doing to manage this concern?” in order to establish a baseline understanding of this 
concern. The summarize, empathize, and direct framework is then used to summarize back to 
the patient what the physician has been told, empathize with the patient’s struggles, and finally 
offer direction toward actionable solutions. 
 
This direction begins with nutrition education, and is followed by sharing of nutrition materials 
specific to the Chinese setting, including illustrations to explain what a healthy diet is. These 
materials include the Chinese Food Guide Pagoda, a culturally specific analogue to the food 
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pyramid developed by the Chinese Nutrition Society, and the Healthy Plate Suitable for Chinese 
Diet, developed by the Chinese Diabetes society. The final component included in this first 
consultation returns to the patient’s original concern, and goes through a problem solving and 
goal setting process to address this concern. This process begins with the use of the Bright 
IDEAS framework from the FLEX Study.82 This framework is accompanied by a visual diagram 
of the framework (Appendix X), and starts with identifying what the patient wishes to change. 
The patient is then shown the Wheel of Change (Appendix X), which helps the patient to identify 
how ready they are to make a change. The patient is then shown the Decisional Balance Scales 
(Appendix X) to assist the patient in recognizing their willingness to change. The patient is next 
asked to define choices for how to make this change in diabetes self-management, which is 
followed by evaluation of these choices to identify the best option. The second Decisional 
Balance Scale measuring confidence in being able to make a change is shared with the patient. 
The fourth step in the Bright IDEAS framework aims to act out and envision the proposed goal 
for addressing the patient’s concern. The consultation ends with the physician and patient 
making plans to see how this goal worked at their next consultation. 
 
The second consultation is written to review old goals and set new ones. The visit starts with a 
review of the patient’s experience with the goal they set during their first visit and is followed by 
the introduction of possible new concerns. New concerns are addressed as in consultation one. 
Sharing of concerns is followed by specific nutrition education to reinforce information about 
carbohydrates and formal carbohydrate counting, as well as reviewing their meal plan and 
challenges to adherence. The dialogue returns to the patient’s dietary challenges, which are 
worked through using the Summarize, Empathize, and Direct format detailed in consultation 
one. These challenges are then addressed using the Bright IDEAS framework, including the 
Wheel of Change and Decisional Balance Scales, as described in consultation one. A change is 
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identified, goals for making this change are defined and evaluated, and the best goal is acted 
out. Plans for the next visit are made, marking the end of consultation two. 
 
The third consultation, which also serves as the basis for all future consultations, continues to 
review prior goals and provides the space for the patient to raise new concerns. The 
Summarize, Empathize, and Direct framework of motivational interviewing and the Bright IDEAS 
framework for problem solving and goal setting continue throughout, allowing for constant 
refinement of the patient’s diabetes self-management. 
 
Patient Recruitment and Baseline Visit 
The new T1D clinic at PKUPH opened in June 2017, in which only patients with T1D were seen 
within an outpatient setting.  For this initial program evaluation, patient recruitment began in 
October 2017 and concluded in March 2018, during which 40 patients were screened as 
eligible, consented, and recruited from first the outpatient and later the inpatient setting.  A 
medical record review was performed to collect demographic characteristics and baseline 
clinical data. After being successfully recruited, participants were asked to complete the DISS, 
the DSMP, and the Intention and Motivation Questionnaire prior to their first consultation using 
the new protocol. 
 
After completing these questionnaires patients received the new consultation from the attending 
endocrinologist, either individually or in a group setting simultaneously with one to two other 
participants. Dr. Liu, the endocrinologist delivering the consultations, adapted the script to her 
own needs, and did not make use of the Wheel of Change or Decisional Balance Scales. 
Though the protocol was written to last for 15-20 minutes, the consultation actually lasted for 30-
40 minutes. 
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Patient Follow-Up 
Patients were asked to return for their second consultation a month following their baseline visit, 
during which time they would complete the same set of questionnaires as they had completed 
prior to their first consultation, including the DISS, DSMP, and Intention and Motivation 
Questionnaire, in order to perform a pre-post analysis. Patients who returned in-person to the 
hospital were asked to complete paper versions of these surveys prior to receiving their second 
consultation. However, of the 40 participants originally recruited, only 4 returned for their second 
consultation within the timeframe of this initial program evaluation. In order to increase follow-up 
data, the questionnaires were compiled into an electronic format using Qualtrics survey 
distribution software, and personalized links were sent to each patient for completion using 
WeChat, a popular messaging application in China. This strategy increased follow-up yield to 23 
responses (57.5%) by the end of the evaluation timeline. 
 
Statistical Analysis 
Demographic and clinical data were used to characterize the study sample at baseline, and 
baseline psychosocial data was used to describe baseline satisfaction, diabetes self-
management skill, and intention and motivation to self-manage. Satisfaction (DISS) scores were 
calculated by adding together the numerical responses to each of the ten questions, with 
negatively worded questions reversed on the Likert scale (1-5) and positively worded questions 
remaining unchanged. Self-management skill scores (DSMP) were calculated using SAS code 
as used in the FLEX Study.82 Though this validated code accounted for unanswered questions, 
surveys with fewer than half of the questions answered (11 or fewer questions answered) were 
excluded from analysis. Intention scores were computed by averaging responses to the first four 
questions of the Intention and Motivation questionnaire, and motivation scores were computed 
by averaging the latter four questions. Baseline characteristics were compared between those 
who provided follow-up data and those who did not in order to assess potential for selection bias 
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using a two-sample mean analysis assuming unequal variance. Among those with follow-up 
data available, a pre-post analysis was performed using a matched pair Student’s t-test to 
analyze changes in patient satisfaction, self-management skill, and intention and motivation to 
self-manage before and after undergoing the first consultation.  
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RESULTS 
 
There were a total of 40 participants recruited at baseline for this program evaluation, and 23 
participants completed follow-up questionnaires. Incomplete data and unavailability of certain 
clinical data resulted in the decrease of in the n of certain variables, as noted in each table. A 
demographic description of the study sample is presented in Table 3.1. This sample contained a 
wide range in age and duration of diabetes. The sample is approximately equally represented 
by sex (55% female, n=22)), and is mostly an urban (79%, n=31), highly educated at a college 
level or higher (62.5%, n=25), and employed (95%, n=37) group. Most individuals receive 
insurance from the government provided to urban residents (90%, n=36), and a majority of 
patients were recruited from the inpatient setting at the PKUPH (85%, n=34). 
 
Table 3.1: Demographic Description of Study Sample (n=40). 
Variable Mean ± St. Dev. or Count (%) 
Age (years) 41.7 ± 16.1 
Time since Diagnosis (years) 8.5 ± 9.0 
Sex  
Female 22 (55%) 
Male 18 (45%) 
Patient Recruitment Location  
Inpatient 34 (85%) 
Outpatient 6 (15%) 
Residence (n=39)  
Urban 31 (79%) 
Rural 8 (21%) 
Educational Level  
Primary or Below 3 (7.5%) 
Secondary 9 (22.5%) 
Vocational 3 (7.5%) 
College or Higher 25 (62.5%) 
Employment (n=39)  
Employed 37 (95%) 
Unemployed 2 (5%) 
Type of Insurance  
Government-provided, Urban 36 (90%) 
Other 4 (10%) 
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Table 3.2 displays the baseline clinical description of the study sample. Target values were 
obtained from recommendations for Chinese patients with type 2 diabetes.83 The glycemic 
control of this sample was very poor, with an average HbA1c level of 9.9%, well above the 
target of 7.0% or below. A majority of the sample was outside of the target range for body mass 
index (BMI), with 27.5% being underweight and 20.0% being overweight. Systolic blood 
pressure targets were met by 72.5% of the sample, while this value dropped to 62.5% when 
considering the diastolic target. Lipid values for this sample were mixed, with a majority meeting 
targets for serum triglycerides and HDL-cholesterol, while nearly half were above the target for 
total cholesterol and nearly two-thirds above the target for LDL-cholesterol.  
 
Table 3.2: Clinical Description of Study Sample with Target Values. 
Clinical Measurement Baseline Mean 
± St. Dev. 
Target Value Outside Target 
Range, n (%) 
HbA1c (%), n=37 9.9 ± 2.3 <7.0% 35 (94.6%) 
BMI (kg/m2) 21.9 ± 3.8 20-24 kg/m2 11 (27.5%) Under 
8 (20.0%) Over 
Blood Pressure (mmHg)    
Systolic 129.6 ± 15.3 <140 mmHg 11 (27.5%) 
Diastolic 78.5 ± 11.2 <80 mmHg 15 (37.5%) 
Lipid Panel, n=39    
Serum Triglycerides (mmol/L) 1.1 ± 0.6 <1.7 mmol/L 5 (12.8%) 
Total Cholesterol (mmol/L) 4.6 ± 1.2 <4.5 mmol/L 18 (46.2%) 
HDL (mmol/L) 1.3 ± 0.4 >0.9 mmol/L  3 (7.7%) 
LDL(mmol/L) 3.0 ± 1.0 <2.6 mmol/L 25 (64.1%) 
 
Table 3.3 shows baseline psychosocial outcomes across all recruited patients. It was shown 
that patient baseline satisfaction with prior physician’s visits, scored out of 50, was high, already 
starting at the upper quintile of scoring. Intention and motivation to self-manage also started at 
the upper end of their respective scales at baseline, both of which are scored out of 10. Self-
management score, however, started lower on its scale, scored out of 86. 
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Table 3.3: Psychosocial Outcomes at Baseline, n=34. 
Psychosocial Measurement Mean Score, Baseline 
Satisfaction Score, out of 50 (n=37) 41.5 ± 6.3 
Self-Management Score, out of 86 46.2 ± 10.7 
Intention Score, out of 10 8.7 ± 2.2 
Motivation Score, out of 10 7.9 ± 2.5 
 
Table 3.4: Comparison of Non-respondent and Respondent to Follow-Up Groups. 
Variable Non-
Respondent 
Group (NR) 
Mean ± St. Dev. 
or Count (%) 
(n=17) 
Respondent 
Group (R) 
Mean ± St. 
Dev. or Count 
(%) 
(n=23) 
Mean 
Difference 
or 
Proportion 
Difference 
p-Value 
HbA1c (%)1 10.3 ± 3.0 9.7 ± 1.7 0.6 0.49 
Age (years) 48.2 ± 15.3 36.8 ± 15.2 11.4 0.03 
Time since Diagnosis (years) 8.5 ± 9.0 8.5 ± 9.0 0.7 0.80 
Sex    0.40 
Female 8 (47%) 14 (61%) 14%  
Male 9 (53%) 9 (39%) 14%  
Patient Recruitment Location    0.01 
Inpatient 17 (100%) 17 (74%) 26%  
Outpatient 0 (0%) 6 (26%) 26%  
Residence2    0.70 
Urban 14 (82%) 17 (77%) 5%  
Rural 3 (18%) 5 (23%) 5%  
Educational Level    0.48 
Primary or Below 2 (12%) 1 (4%) 7%  
Secondary 4 (24%) 5 (22%) 2%  
Vocational 1 (6%) 2 (9%) 3%  
College or Higher 10 (59%) 15 (65%) 6%  
Employment3    0.29 
Employed 15 (94%) 22 (96%) 2%  
Unemployed 1 (6%) 1 (4%) 2%  
Type of Insurance    0.04 
Government, Urban 17 (100%) 19 (83%) 17%  
Other 0 (0%) 4 (17%) 17%  
1nNR=16, nR=21; 2nR=22; 3nNR=16 
 
Demographic variables and HbA1c were compared between those who did not complete follow-
up questionnaires, termed non-respondent, and those who did, termed respondent. The results 
are presented in Table 3.4. This comparison demonstrated that the two groups were not 
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significantly different in HbA1c, diabetes duration, sex, residence, education, and employment. 
The comparison showed that the respondent group was younger, had a lower ratio of outpatient 
to inpatient participants, and was more comprised of those with governmental urban insurance. 
 
The results of the matched-pair analysis are displayed in Table 3.5. The average time between 
baseline and follow-up was 70.6±41.1 days. The mean DSMP score for the matched pair 
sample increased from 47.8 to 56.0 out of 86, representing a highly significant (p<0.001) 
increase in diabetes self-management skills. The average motivation score for the matched pair 
sample increased from 8.3 to 9.4 out of 10, representing a significant (p=0.028) increase. The 
average patient satisfaction for the patched pair sample decreased marginally from 42.6 to 42.3 
out of 50, but this was not a significant change. The average intention score for the matched 
pair sample increased from 8.9 to 9.3 out of 10, but this did not represent a significant change. 
 
Table 3.5: Psychosocial Outcomes on Patient Satisfaction (n=20), Self-Management Skill 
(n=20), Intention to Self-Manage (n=19), and Motivation to Self-Manage (n=19). 
 
Psychosocial 
Measurement 
Mean Score, 
Baseline 
Mean Score, 
Follow-up Difference (95% CI) p-Value 
Satisfaction Score 42.6 ± 7.2 42.3 ± 7.3 -0.3 (-2.7 to 2.1) 0.796 
Self-Management 
Score 
47.8 ± 8.5 56.0 ± 9.0 8.2 (3.9 to 12.4) <0.001 
Intention Score 8.9 ± 0.9 9.3 ± 0.9 0.5 (-0.1 to 1.0) 0.329 
Motivation Score 8.3 ± 1.1 9.4 ± 0.9 1.2 (0.6 to 1.8) 0.028 
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DISCUSSION 
 
The new consultation protocol for type 1 diabetes that was developed for this study addresses 
many deficiencies in the status of clinical care delivery among this patient population and 
responds to recommendations offered by existing literature. One study identified that 
carbohydrate counting is a skill that many patients with T1D in China lack,22 and recommended 
that diabetes care delivery emphasize increased frequency of nutrition education, along with 
bolstered self-monitoring of blood glucose. This consultation directly responds to this disparity 
by providing nutrition education to the patients, and specifically includes carbohydrate counting 
as a skill that is taught. The Joslin Diabetes Center’s identified three overarching themes in 
modifiable targets for improved psychosocial care of diabetes: knowledge and beliefs, emotional 
status of the patient, and behavioral skills.84 The consultation responds to all three through its 
provision of nutrition education, emotional support through a framework of motivational 
interviewing and problem solving, and practical goal setting to yield improved diabetes self 
management skills. 
 
Baseline patient satisfaction, intention to self-manage, and motivation to self-manage started on 
the upper ends of their relative scales, suggesting that patients were relatively satisfied with 
care delivery and feeling intent and motivated to self-manage their diabetes prior to receiving 
the new consultation. Baseline self-management skill was relatively low compared to the 
literature, which reported baseline DSMP scores ranging from 53.0 to 62.7 out of 86.85-87 
However, after one consultation, the mean DSMP score rose to 56.0±9.0 and therefore met this 
baseline range in the literature. In evaluating of the consultation across a matched-pair sample, 
we demonstrated a significant increase in both diabetes self-management skill and motivation to 
self-manage after completing one consultation using the new clinical consultation protocol when 
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compared to baseline. However, a significant change in neither patient satisfaction nor intention 
to self-manage was seen. 
 
The average HbA1c of 9.9% indicates very poor status of glycemic control in this sample, and is 
higher than average HbA1c values reported for Beijing of 8.3%16 and for China of 9.5%.68 The 
high mean HbA1c was likely influenced by the majority of the sample being recruited from the 
inpatient setting of PKUPH, which represents a patient subset dealing with chronically poor 
glycemic control and recent hospitalization due to severe complications, particularly DKA and 
hypoglycemia. The high average HbA1c of this sample, though indicative of the disproportionate 
representation of very poorly controlled cases of T1D, is also able to demonstrate that this new 
consultation is reaching the individuals at highest risk and in greatest need of intensive 
improvement of clinical care being delivered.  The proportion of individuals found to have both 
systolic (27.5%) and diastolic (37.5%) hypertension is higher than the IDF’s reported 
hypertension prevalence of 23.9% in China,68 and potentially is also the result of the high 
proportion of participants recruited from the inpatient setting. 
 
A nationally representative cross-sectional 2013 study surveyed the general Chinese adult 
population (Table 3.6). This study reported a mean age of 43.5±16.2, which closely matches the 
mean age found in this program evaluation’s sample. The reported clinical values are presented 
below. Our sample has a lower BMI, but closely matches the general Chinese adult population 
in terms of systolic blood pressure, total cholesterol, and HDL cholesterol.  
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Table 3.6: Clinical Characteristics of the General Chinese Adult Population54 (n=170,287) 
Compared with the Present Study’s Findings (n=40, nHbA1c=37). 
 
Clinical Measurement Baseline Mean 
± St. Dev., 
Wang 2017 
Baseline Mean 
± St. Dev., 
Present Study 
HbA1c (%) 5.38 ± 0.83 9.9 ± 2.3 
Body Mass Index (kg/m2) 24.0 ± 3.7 21.9 ± 3.8 
Blood Pressure (mmHg)   
Systolic 127.9 ± 20.0 129.6 ± 15.3 
Diastolic —  78.5 ± 11.2 
Lipid Panel, n=39   
Serum Triglycerides (mmol/L) — 1.1 ± 0.6 
Total Cholesterol (mmol/L) 4.7 ± 1.0 4.6 ± 1.2 
HDL (mmol/L) 1.3 ± 0.4 1.3 ± 0.4 
LDL(mmol/L) — 3.0 ± 1.0 
 
 
Strengths and Limitations 
There were limitations to this study. Though the originally anticipated sample size of this study 
was 150, we were only able to recruit 40 patients at baseline and obtain 23 follow up responses, 
which was small relative to the statistical significance we aimed to identify. This program 
evaluation’s setting, including delays in the opening of the T1D clinic and the busy clinical 
environment of the PKUPH, influenced our low recruitment rate. However, as this study was not 
a randomized control trial, limited recruitment serves to describe the program evaluation’s 
setting rather than detract from its validity.  
 
Low follow-up also limited our results, as we expected patients to return to the clinic monthly to 
receive a new prescription for insulin. However, it later became clear that patients could see 
other doctors to get their prescription without seeing WL and undergoing the consultation, and 
could inadvertently miss follow-up consultations. With only 23 of the 43 originally recruited 
participants providing follow-up data, the statistical power behind the matched pair analyses 
was lacking. In addition, the fact that mean satisfaction, intention, and motivation scores were all 
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already near the upper end of their respective scales further limited our ability to detect changes 
in these outcomes. Missing data in both baseline and follow-up time points compounded these 
limitations to data analysis. Missing data could be attributed to survey taker fatigue, especially in 
the hospital setting in which patients have already spent extended periods of time waiting to be 
seen and may wish to limit further time spent taking surveys. WL’s ability to review surveys to 
ensure completeness was impractical, since WL informed patients that she would not view their 
responses in order to encourage honest responses, particularly regarding patient satisfaction. 
 
Both baseline and follow-up data were limited by the lack of consistency in several ways. At 
baseline, the first 10 participants completed questionnaires electronically, but following technical 
issues, the remaining 30 participants completed paper surveys. Variability was also introduced 
when some study participants received the consultation in private, while others received group 
consultations with 1 or 2 other patients. There was additional variability in the time between 
baseline and follow-up, and the format in which these follow-up surveys were taken, with 4 
patients completing them in person prior to undergoing their second consultation at the T1D 
clinic, while the other 19 completed them electronically outside of the clinical setting. This 
variation in data collection format increases the likelihood of information bias secondary to 
incorrect entry to data from paper surveys and Qualtrics links into the RedCap software. 
Selection bias is a limitation that must be acknowledged. This study drew mostly from the 
inpatient setting, representing more severe cases of T1D. Furthermore, the comparison of 
respondent to follow-up and non-respondent to follow-up groups at baseline shows that there 
are significant differences between the two, which should be recognized when viewing our 
findings. 
 
A final limitation of this study, the variability inherent to WL’s delivery of the consultation, can 
also be seen as one of this study’s greatest strengths. Considering how no one patient is the 
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same, WL used the consultation protocol as a starting point, but modified her consultation 
approach following each patient encounter as she learned what worked and what she would 
rather leave out. The consultation protocol, therefore, entails a strength in its a versatility as a 
guide to assist endocrinologists in effectively communicating with a wide variety of patients with 
T1D, each with their individual concerns. The incorporation of group consultations was an 
interesting example of the versatility of this consultation. WL noticed that many patients shared 
similar concerns, and found this strategy advantageous in time effectiveness and in creating a 
space for patients to share their concerns with each other, and enjoy social support and shared 
learning. 
 
There are additional strengths to this study that are important to recognize. WL’s collaboration 
was invaluable towards our efforts. She served as the champion at PKUPH who lead the efforts 
to create the T1D clinic and therefore space for the delivery of this consultation. Having the 
direct support of the Department of Endocrinology at PKUPH, a major clinical center was also 
advantageous to our ability to conduct this program evaluation. 
 
Development of the consultation drew from the literature on using motivational interviewing 
during a patient-provider consultation as well as using problem solving and goal setting to 
address concerns surrounding diabetes self-management. In this way, the consultation draws 
from evidence-based strategies that are specific to the clinical setting encountered in this study. 
Lastly, the data collection instruments used in this study, including the Diabetes Interview 
Satisfaction Survey (DISS), the Diabetes Self-Management Questionnaire (DSMP), and the 
Intention and Motivation Questionnaire, were all validated and all sourced from existing peer-
reviewed studies.  
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
Compared to baseline, this program evaluation demonstrated a significant increase in diabetes 
self-management skill and motivation to self-manage among participants. Significant changes in 
patient satisfaction and intention to self-manage were not demonstrated. 
 
An immediate future step involves obtaining follow-up clinical data, particularly HbA1c values, in 
order to investigate the impact of the new consultation on this critical outcome. Future work 
could also introduce measures of quality of life to investigate whether the improvement in self-
management and motivation as observed in this program evaluation would translate into these 
patients’ ability to find financial and physical wellbeing, pursue and sustain meaningful 
relationships, engage in their preferred occupation, develop personally and intellectually, and 
enjoy a fulfilling social life. 
 
Since our research was a pilot study, next steps include repeating this study with a larger 
sample size. Though our study had significant findings, the sample size was still limiting relative 
to the statistical significance we aimed to identify. Potential avenues for increasing patient 
recruitment and the scope of the program evaluation would be to train additional 
endocrinologists to deliver this consultation and to expand use of the consultation to multiple 
clinical sites around China. Higher percent follow-up is also of interest and would require 
consideration of how to better encourage return visits and identification of potential barriers to 
follow-up. Pursuing higher follow-up rates would also entail reconsidering the timeline to 
potentially conduct consultations less frequently, perhaps on a quarterly rather than monthly 
basis. Such a change would require this next study to be conducted over a longer timeframe, 
which could allow for ongoing assessment of changes in outcomes beyond one consultation. 
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As evidenced by the lack of significant improvement in patient satisfaction and intention to self-
manage, another important future step for this project would be to amend the consultation 
protocols to target these outcomes. An avenue to address these amendments is to conduct a 
formal interview with WL and other endocrinologists and to conduct focus groups with study 
participants in order to garner feedback on how the consultation protocol can be refined to 
better meet both provider preferences and patient needs. Further development of the 
consultation in this manner should particularly take into account the success of group 
consultations that were observed and evaluate the effectiveness of group versus singular 
consultations. 
 
The significant improvement in self-management skill and motivation to self-manage is an 
important and promising first step to provide a bases upon which future work can be built and to 
encourage the continuation of our investigation into how diabetes care in China can continue to 
be advanced.  
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CHAPTER FOUR 
ADDITIONAL ANALYSES AND CONSIDERATIONS 
 
Initially, this program evaluation aimed to analyze changes in clinical measurements, particularly 
HbA1c. However, follow-up clinical data beyond baseline was not available during the timeframe 
of this project, and therefore this analysis could not be performed and this component of the 
original aim could not be investigated. Additionally, the likelihood that statistically significant 
findings in the matched-pair analysis were the product of chance is increased secondary to the 
small sample size, considering that a finding seen in this small sample may not be seen in other 
samples of a similar size.  
 
In confronting our low patient recruitment, the researchers working on this study located at the 
University of North Carolina at Chapel Hill arranged to have weekly calls with WL in Beijing, 
China to encourage continued patient recruitment efforts in spite of the busy clinical 
environment at PKUPH. The researchers on this study also strategized around low follow-up 
data attainment, deciding to send out follow-up questionnaires electronically in Qualtrics survey 
format via WeChat, a popular messaging application in China. This decision was immensely 
important, as the vast majority of our follow up data came form this method of data collection.  
 
Subgroup analyses were performed on the matched pairs on the demographic factors of age, 
T1D duration, sex, and education, and the clinical variable of HbA1c (Table 4.1). The four 
demographic variables were dichotomized relative to the sample median for each variable, and 
HbA1c was dichotomized using a standard of 9% as a marker of poor glycemic control in 
individuals with diabetes. 
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Table 4.1: Subgroup Analyses on Matched-Pairs Across Variables of Age, Diabetes Duration, 
Sex, Education, and HbA1c. 
 
Subgroup Patient Satisfaction Baseline Follow-up Difference n p-Value 
Age <43 years 42.9 43.3 0.4 14 0.739 ≥43 years 42.0 40.0 -2.0 6 0.454 
Diabetes 
Duration 
≤5 years 39.7 41.2 1.6 9 0.400 
>5 years 45.0 43.2 -1.8 11 0.227 
Sex Male 45.5 46.3 0.8 8 0.744 Female 40.7 39.7 -1.0 12 0.443 
Education 
Vocational, 
secondary, or lower 38.2 37.2 -1.0 6 0.497 
College or higher 44.5 44.5 0.0 14 1.00 
HbA1c <9% 41.3 40.6 -0.6 8 0.551 ≥9% 43.5 43.4 -0.1 12 0.964 
 
Subgroup Diabetes Self-Management Skill Baseline Follow-up Difference n p-Value 
Age <43 years 50.2 56.0 5.8 13 0.028 ≥43 years 43.4 55.9 12.5 7 0.013 
Diabetes 
Duration 
≤5 years 48.4 54.7 6.3 11 0.062 
>5 years 47.1 57.4 10.4 9 0.004 
Sex Male 45.4 51.8 6.4 9 0.034 Female 49.8 59.4 9.6 11 0.012 
Education 
Vocational, 
secondary, or lower 46.9 49.8 2.9 6 0.412* 
College or higher 48.2 58.6 10.4 14 0.0007* 
HbA1c <9% 50.6 58.3 7.7 7 0.063 ≥9% 46.3 54.7 8.4 13 0.008 
 
Subgroup Intention to Self Manage Baseline Follow-up Difference n p-Value 
Age <43 years 8.7 9.5 0.9 11 0.299 ≥43 years 9.1 9.1 0.0 8 0.938 
Diabetes 
Duration 
≤5 years 9.0 9.2 0.2 9 0.747 
>5 years 8.7 9.5 0.8 10 0.370 
Sex Male 8.0 9.8 1.8 6 0.229 Female 9.3 9.2 -0.1 13 0.779 
Education 
Vocational, 
secondary, or lower 7.8 8.6 0.8 6 0.610 
College or higher 9.3 9.7 0.3 13 0.19 
HbA1c <9% 8.4 9.5 1.0 8 0.347 ≥9% 9.2 9.3 0.1 11 0.825 
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Subgroup Motivation to Self-Manage Baseline Follow-up Difference n p-Value 
Age <43 years 8.7 9.5 0.8 11 0.312 ≥43 years 7.7 9.4 1.8 8 0.033 
Diabetes 
Duration 
≤5 years 8.8 9.5 0.7 9 0.190 
>5 years 7.8 9.4 1.6 10 0.088 
Sex Male 8.1 9.3 1.3 6 0.344 Female 8.3 9.5 1.1 13 0.046 
Education 
Vocational, 
secondary, or lower 8.0 9.4 1.4 6 0.335 
College or higher 8.4 9.5 1.1 13 0.038 
HbA1c <9% 7.8 10.0 2.2 8 0.041 ≥9% 8.6 9.0 0.4 11 0.399 
 
 
The main significant finding of this analysis is seen in the education subgroups for diabetes self-
management skill, which shows that while self-management ability improved significantly for 
participants who were college educated or higher, the same did not hold true for those of a 
lower education attainment. This finding indicates that the consultation was more effective at 
improving self-management skills among those who come from a higher educational 
background, and indicates the need for future work to better help patients of lower educational 
status with these skills. 
 
The remaining subgroups for self-management skill did not show large differences. Subgroup 
differences in motivation were apparent, with motivation improving more significantly in 
subgroups that were older, were female, more educated, and had better glycemic control. 
However, these differences were of marginal statistical significance. The diabetes duration 
subgroups did not demonstrate a significant difference in motivation to self-manage, and no 
subgroup differences were noted in patient satisfaction or intention to self-manage. This 
analysis is limited by the small sample size in each subgroup. 
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Today’s Date: ____/____/____            PID_____________Staff ID  
                   dd    mm   yyyy 
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Program evaluation of a T1D clinic at Peking University People’s Hospital in Beijing, China  
Demographic and Clinical Data Form 
 
This form is to be completed for eligible, recruited, and consenting study participants. For missing dates, 
note day and month  “99” and missing year as “9999.” Other questions can be noted as missing if 
applicable.  
1. What is the participant’s sex?  
qMale  
qFemale  
qUnknown  
 
2. What is the participant’s diagnosis date? 
 
 
 
 
 
 
3. What is the date of most recent endocrinology visit?  Note: Please review and update within 
one week of the baseline visit.  
 
 
 
 
 
4.  How many diabetes clinic visits has the patient had in the previous year?  
q	0		
q	1		
q	2		
q	3		
q	4	or	more		
q	Unknown	
 
5. What kind of health insurance does the participant have? Mark yes or no for each 
 
Yes  No  Types of Insurance 
q q Basic Government Insurance 
q q Employer-Provided Insurance  
q q Basic Government Insurance + Employer Support 
q q Private Insurance 
q q Other __________________________________  
q q None/self-paying 
q q Don’t know/missing  
  Day      Month             Year 
  Day      Month             Year 
Today’s Date: ____/____/____            PID_____________Staff ID  
                   dd    mm   yyyy 
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6. Lab measurements: Fill out as many as six measurements since one year prior to patient's first 
Clinic visit. 
 
Lab Measurement  Value  Date (dd/mm/yyyy) 
 from least to most recent 
A. HbA1c                                            %           /          / 
                                           %           /          / 
                                           %           /          / 
                                           %           /          / 
                                           %           /          / 
                                           %           /          / 
B. Blood Pressure 
(systolic/diastolic) 
 
 
 
                    /                      mmHg           /          / 
                    /                      mmHg           /          / 
                    /                      mmHg           /          / 
                    /                      mmHg           /          / 
                    /                      mmHg           /          / 
                    /                      mmHg           /          / 
C. Height                                             cm           /          / 
                                            cm           /          / 
                                            cm           /          / 
                                            cm           /          / 
                                            cm           /          / 
                                            cm           /          / 
D. Weight 
 
 
 
                                            kg           /          / 
                                            kg           /          / 
                                            kg           /          / 
                                            kg           /          / 
                                            kg           /          / 
                                            kg           /          / 
E. Waist Circumference 
 
 
 
                                            cm           /          / 
                                            cm           /          / 
                                            cm           /          / 
                                            cm           /          / 
                                            cm           /          / 
                                            cm           /          / 
F. Hip Circumference 
 
 
 
                                            cm           /          / 
                                            cm           /          / 
                                            cm           /          / 
                                            cm           /          / 
                                            cm           /          / 
                                            cm           /          / 
Today’s Date: ____/____/____            PID_____________Staff ID  
                   dd    mm   yyyy 
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G. Triglycerides 
 
 
 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
H. Cholesterol, Total 
 
 
 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
I. HDL 
 
 
 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
J. LDL 
 
 
 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
                                          mmol/L           /          / 
K. C-peptide 
 
 
 
                                            ng/mL           /          / 
                                            ng/mL           /          / 
                                            ng/mL           /          / 
                                            ng/mL           /          / 
                                            ng/mL           /          / 
                                            ng/mL           /          / 
L. GAD Antibodies 
 
 
 
                                            RU           /          / 
                                            RU           /          / 
                                            RU           /          / 
                                            RU           /          / 
                                            RU           /          / 
                                            RU           /          / 
 
 
 
 
Today’s Date: ____/____/____            PID_____________Staff ID  
                   dd    mm   yyyy 
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M. Urine Albumin 
 
 
 
                                         mg/mmol           /          / 
                                         mg/mmol           /          / 
                                         mg/mmol           /          / 
                                         mg/mmol           /          / 
                                         mg/mmol           /          / 
                                         mg/mmol           /          / 
N. Urine Creatinine 
 
 
 
                                         mL/min           /          / 
                                         mL/min           /          / 
                                         mL/min           /          / 
                                         mL/min           /          / 
                                         mL/min           /          / 
                                         mL/min           /          / 
 
今天的日期: ____/____/____            PID_____________Staff ID  
                   日    月   年 
 
 
北京大学人民医院一型糖尿病   划 估  
人口和  数据表  
合格 聘自愿同意参加者需要填写此表格. 如有漏掉的日期， 在日和月 填写“99”，
在年 填写“9999”。如有其他地方可以留空白. 
 
1. 参加者性 ? 
q男  
q女  
q不明  
 
2. 参加者被诊断日期  
 
 
 
 
 
3. 最近一次看内分泌科的日期？注重：请回顾并更新一周内的资料。 
 
 
 
 
4. 在去一年你有看了几次糖尿病 诊？ 
q	0		
q	1		
q	2		
q	3		
q	多于 4	
q	不知道	
 
5. 你持有哪一种健康保险？请在下面填上是或不是 
是   不是   保险种类  
q q 基本政府保  
q q 雇主-提供的保  
q q 基本政府保  + 雇主-提供的保  
q q 私人保险 
q q 其他 __________________________________  
q q 没保险/自付 
q q 不知道/缺乏资料 
  日       月              年  
  日       月              年  
Today’s Date: ____/____/____            PID_____________Staff ID  
                   dd    mm   yyyy 
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6. 实验室捡测：请填上你在第一次看门诊前一年的捡测结果 
实验室捡测  捡测结果  日期（日 / 月 / 年）  
从最早到最近 
A. HbA1c                                            %           /          / 
B. 血  (收缩压/舒张压)                     /                      mmHg           /          / 
C. 身高                                             cm           /          / 
D. 体重                                             kg           /          / 
E. 腰围                                             cm           /          / 
F. 盘围                                             cm           /          / 
G. 甘油三酯                                             mmol/L           /          / 
H. 总胆固醇                                             mmol/L           /          / 
I. 高密度脂肪                                             mmol/L           /          / 
J. 低密度脂肪                                             mmol/L           /          / 
K. C-肽                                             ng/mL           /          / 
L. 尿白蛋白                                          mg/mmol                  /          / 
M. 尿肌酐                                          mL/min                  /          / 
N. GAD抗体                                             RU           /          / 
Today’s Date: ____/____/____            PID_____________Staff ID  
                   dd    mm   yyyy 
 
Program evaluation of a T1D Clinic at Peking University People’s Hospital in Beijing, 
China  
Clinical Data Update Form 
 
This form is to be completed after each clinic visit. For missing dates, note day and month as  “99” and 
missing year as “9999.” 
1. Is the participant now pregnant? 
q Yes 
q No 
q Not applicable – male participant 
q Unknown/missing  
 
2. Lab Measurement  Value   
A. HbA1c 
 
                                           % 
  
q Not measured/missing 
B. Blood Pressure 
(systolic/diastolic) 
                    /                     mmHg 
 
q Not measured/missing 
C. Weight                                            kg 
 
q Not measured/missing 
D. Waist Circumference                                            cm 
  
q Not measured/missing 
E. Hip Circumference                                            cm 
  
q Not measured/missing 
F. Height                                           cm 
 
q Not measured/missing 
G. Triglycerides                                           mmol/L 
 
q Not measured/missing 
H. Cholesterol, Total                                           mmol/L 
 
q Not measured/missing 
I. HDL                                           mmol/L 
 
q Not measured/missing 
J. LDL                                           mmol/L 
 
q Not measured/missing 
K. C-peptide                                           ng/mL 
 
q Not measured/missing 
L. GAD Antibodies                                           RU 
 
q Not measured/missing 
M. Urine Albumin 
 
                                          mg/mmol q Not measured/missing 
N. Urine Creatinine 
 
                                          mL/min q Not measured/missing 
  
Appendix B: Consent Form, Parental Consent Form, and Youth Assent Form with Chinese 
Translations 
 
                                                                            
University of North Carolina at Chapel Hill 
Consent to Participate in a Research Study 
Adult Participants 
Consent Form Version Date: 04/24/17 
IRB Study: 17-1044 
Title of Study: Program Evaluation of a Type 1 Diabetes Clinic at Peking University People’s Hospital in 
Beijing, China  
Principal Investigator: Elizabeth Mayer-Davis 
Principal Investigator Department: Nutrition Operations 
Principal Investigator Phone number: (919) 966-7218 
Principal Investigator Email Address: mayerdav@email.unc.edu  
Co-Investigators: Wei Liu, Jennifer Lyu, Sanjay Gadi 
______________________________________________________________ 
 
What are some general things you should know about research studies? 
You are being asked to take part in a research study. To join the study is voluntary. 
You may refuse to join, or you may withdraw your consent to be in the study at any time, for any reason, 
without penalty. 
 
Research studies are designed to obtain new knowledge. This new information may help people in the 
future. You may not receive any direct benefit from being in the research study. There also may be risks 
to being in research studies.  
 
Details about this study are discussed below.  It is important that you understand this information so that 
you can make an informed choice about being in this research study.  
You will be given a copy of this consent form.  You can ask the researchers named above, or staff 
members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study? 
 
This is a joint study lead by researchers at the University of North Carolina at Chapel Hill and Peking 
University People’s Hospital. The purpose of the project is to improve the clinical experience of patients 
with type 1 diabetes (T1D) in Beijing, China by incorporating motivational interviewing, a patient-
centered communication style, goal setting and problem solving skills training, and nutrition education. It 
is expected that these changes to the traditional diabetes care being delivered to T1D patients in Beijing 
will help them better self-manage their diabetes and have better health outcomes, specifically in regard to 
glucose control.    
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You are being asked to be in the study because you have T1D and are receiving care in the clinic in which 
this study is being performed. 
Who is eligible for this study?  
Adults with T1D older than 18 years;  
Adolescents with T1D ages 15-17 years. 
 
How many people will take part in this study? 
Approximately 100 people will take part in this study, including adults and adolescents with T1D. 
 
How long will your part in this study last? What will you have to do? 
Study participants will be asked to keep their monthly appointments with the Diabetes Clinic and to 
answer a series of questionnaires before and after these visits. Your medical records will be viewed to 
collect the below information, if available, from one year before your first visit to the Diabetes Clinic 
until the end of the study period in June 2018. Study questionnaires will also be administered until June 
2018. The questionnaires and their purpose are listed below. Participants will be asked to spend an extra 
10-15 minutes before and after certain visits to complete these questionnaires. 
 
Data to be collected from medical records: 
HbA1c 
Height 
Weight 
Waist and hip circumference 
Blood pressure 
Lipid profile (total cholesterol, HDL, LDL, triglycerides) 
C-peptide 
GAD antibodies 
Urine albumin 
Urine creatinine 
 
Questionnaires to be administered: 
Nutrition Knowledge and Diet Survey (2) – this questionnaire has two versions: the first version 
includes questions about your past diabetes education relating to nutrition, as well as nutrition 
knowledge; the second version includes evaluation questions regarding the nutrition brochure you 
will be given, as well as nutrition knowledge  
Diabetes Interview Satisfaction Scale (DISS) – this questionnaire will ask about your satisfaction with 
the care being provided at the Diabetes Clinic 
Diabetes Self-Management Survey (DSMQ-SR) – this questionnaire will ask about how you self-
manage your diabetes 
Intention and Motivation Survey – this questionnaire will gauge how intent and motivated you are on 
self-managing your diabetes. 
 
How will information about you be protected? 
You will be given an ID number during participation in the study. The information collected from you in 
the questionnaires and your medical records will not be connected with your name or any other 
information that identifies you. All questionnaires will be administered on an electronic tablet provided in 
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the Diabetes clinic. All the information collected for study purposes will be de-identified (with the 
exception of signed consent forms). There is a minimal potential risk associated with loss of 
confidentiality of health-related information. All paper versions of forms will not contain any identifiable 
information, and will be stored in a locked file cabinet in a locked office in Peking University People’s 
Hospital. However, in the event of an unlikely data breach, all data will be unidentifiable and will not be 
stored with any personal identifiers with the exception of signed consent forms. All discussions of study 
eligibility and participation will also occur in a private setting to protect the privacy of patients and avoid 
accidental status disclosure. Participants will not be identified in any report or publication about this study. 
 
What if you want to stop before your part in the study is complete? 
Your participation in this study is completely voluntary. You can withdraw from this study at any time 
without penalty. Whether or not you decide to participate in this study will have no influence on your 
medical treatment at Peking University People’s Hospital. 
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might affect your 
willingness to continue your participation.  
 
Will you receive anything for being in this study? 
Research is designed to benefit society by gaining new knowledge. You will not receive any monetary 
compensation for your participation in this study. You will receive the same quality of care at the 
Diabetes Clinic whether you choose to participate in the study or not. 
 
What are the possible risks or discomforts involved from being in this study? 
It will not cost you anything to be in this study. The risk for joining in this study is very minimal. The 
surveys may make you mentally tired while answering the questions. If you feel this way from taking the 
survey, you can stop at any time. The medical staff members at the Peking University People’s Hospital 
are trained to counsel and support you and your family. There may be uncommon or previously unknown 
risks. You should report any problems to the researcher.  
 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this research. If you 
have questions about the study, including complaints, concerns, or research-related injuries—which are 
unlikely—you should contact the researchers listed on the first page of this form. 
 
What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your rights and 
welfare.  If you have questions or concerns about your rights as a research subject, or if you would like to 
obtain information or offer input, you may contact the Peking University People’s Hospital Institutional 
Review Board at 010-88324526. 
  
  
                                                                            
 61 
 
Participant’s Agreement: 
 
I have read the information provided above. I have asked all the questions I have at this time. I voluntarily 
agree to participate in this research study. 
  
 
______________________________________________________ 
Signature of Research Participant 
 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Research Participant 
  
 
______________________________________________________ 
Signature of Research Team Member Obtaining Consent 
 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Research Team Member Obtaining Consent 
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University of North Carolina at Chapel Hill 
Parental Permission for a Minor Child to Participate in a Research Study  
Consent Form Version Date: 04/24/17 
IRB Study: 17-1044 
Title of Study: Program Evaluation of Type-1 Diabetes Clinic at Peking University People’s Hospital in 
Beijing, China 
Principal Investigator: Elizabeth Mayer-Davis 
Principal Investigator Department: Nutrition Operations 
Principal Investigator Phone number: (919) 966-7218 
Principal Investigator Email Address: mayerdav@email.unc.edu  
Co-Investigators: Wei Liu, Jennifer Lyu, Sanjay Gadi 
______________________________________________________________ 
 
What are some general things you and your child should know about research studies? 
Your child is being asked to take part in a research study. To join the study is voluntary. 
You may refuse to enroll your child in the study, or you may withdraw your consent for your child to be 
in the study at any time, for any reason, without penalty. 
 
Research studies are designed to obtain new knowledge. This new information may help people in the 
future. You or your child may not receive any direct benefit from being in the research study. There also 
may be risks to being in research studies.  
 
Details about this study are discussed below. It is important that you understand this information so that 
you can make an informed choice about your child’s participation in this research study. You will be 
given a copy of this consent form. You can ask the researchers named above, or staff members who may 
assist them, any questions you or your child have about this study at any time. 
 
What is the purpose of this study? 
 
This is a joint study lead by researchers at the University of North Carolina at Chapel Hill and Peking 
University People’s Hospital. The purpose of the project is to improve the clinical experience of patients 
with type 1 diabetes (T1D) in Beijing, China by incorporating motivational interviewing, a patient-
centered communication style, goal setting and problem solving skills training, and nutrition education. It 
is expected that these changes to the traditional diabetes care being delivered to T1D patients in Beijing 
will help them better self-manage their diabetes and have better health outcomes, specifically in regard to 
glucose control.    
Your child is being asked to be in the study because he or she has T1D and is receiving care in the clinic 
in which this study is being performed. 
Who is eligible for this study?  
Adults with T1D older than 18 years; 
Adolescents with T1D ages 15-17 years. 
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How many people will take part in this study? 
Approximately 100 people will take part in this study, including adults and adolescents with T1D. 
 
How long will your child’s part in this study last? What will your child have to do? 
Study participants will be asked to keep their monthly appointments with the Diabetes Clinic and to 
answer a series of questionnaires before and after these visits. Your child’s medical records will be 
viewed to collect the below information, if available, from one year before his or her first visit to the 
Diabetes Clinic until the end of the study period in June 2018. Study questionnaires will also be 
administered until June 2018. These questionnaires and their purpose are listed below. You and your child 
will be asked to spend an extra 10-15 minutes before and after certain visits to complete these 
questionnaires. 
 
Data to be collected from medical records: 
HbA1c 
Height 
Weight 
Waist and hip circumference 
Blood pressure 
Lipid profile (total cholesterol, HDL, LDL, triglycerides) 
C-peptide 
GAD antibodies 
Urine albumin 
Urine creatinine 
 
Questionnaires to be administered: 
Nutrition Knowledge and Diet Survey (2) – this questionnaire has two versions: the first version 
includes questions about your child’s past diabetes education relating to nutrition, as well as 
nutrition knowledge; the second version includes evaluation questions regarding the nutrition 
brochure your child will be given, as well as nutrition knowledge. 
Diabetes Interview Satisfaction Scale (DISS) – this questionnaire will ask about your child’s 
satisfaction with the care being provided at the Diabetes Clinic. 
Diabetes Self-Management Survey (DSMQ-SR) – this questionnaire will ask about how your child 
self-manages his or her diabetes. 
Intention and Motivation Survey – this questionnaire will gauge how intent on and motivated your 
child is to self-manage his or her diabetes. 
 
How will information about your child be protected? 
Your child will be given an ID number during participation in the study. The information collected in the 
questionnaires and medical records will not be connected with your child’s name or any other information 
that identifies him or her. All questionnaires will be administered on an electronic tablet provided in the 
Diabetes clinic. All the information collected for study purposes will be de-identified (with the exception 
of signed consent forms). There is a minimal potential risk associated with loss of confidentiality of 
health-related information. All paper versions of forms will not contain any identifiable information, and 
will be stored in a locked file cabinet in a locked office in Peking University People’s Hospital. However, 
in the event of an unlikely data breach, all data will be unidentifiable and will not be stored with any 
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personal identifiers with the exception of signed consent forms. All discussions of study eligibility and 
participation will also occur in a private setting to protect the privacy of patients and avoid accidental 
status disclosure. Participants will not be identified in any report or publication about this study. 
 
What if your child wants to stop before their part in the study is complete? 
Your child’s participation in this study is completely voluntary. He or she can withdraw from this study at 
any time for any reason without penalty. Whether or not your child decides to participate in this study will 
have no influence on his or her medical treatment at Peking University People’s Hospital. 
 
What if we learn about new findings or information during the study?  
You and your child will be given any new information gained during the course of the study that might 
affect your child’s willingness to continue your participation. 
 
Will you or your child receive anything for being in this study? 
Research is designed to benefit society by gaining new knowledge. You and your child will not receive 
any monetary compensation for your child’s participation in this study. Your child will receive the same 
quality of care at the Diabetes Clinic whether your child participates in the study or not. 
What are the possible costs, risks, or discomforts involved from being in this study? 
It will not cost you or your child anything to be in this study. The risk for joining in this study is very 
minimal. The surveys may make your child mentally tired while answering the questions. If he or she 
feels this way from taking the survey, your child can stop at any time. The medical staff members at the 
Peking University People’s Hospital are trained to counsel and support you and your family. There may 
be uncommon or previously unknown risks. You or your child should report any problems to the 
researcher. 
 
What if you or your child have questions about this study? 
You and your child have the right to ask, and have answered, any questions you may have about this 
research. If you or your child have questions about the study, including complaints, concerns, or research-
related injuries—which are unlikely—you should contact the researchers listed on the first page of this 
form. 
 
What if you or your child have questions about their rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect you and your child’s 
rights and welfare. If you or your child have questions or concerns about his or her rights as a research 
subject, or if you or your child would like to obtain information or offer input, you or your child may 
contact the Peking University People’s Hospital Institutional Review Board at 010-88324526. 
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Parent’s Agreement:  
I have read the information provided above. I have asked all the questions I have at this time. I voluntarily 
give permission to allow my child to participate in this research study. 
  
______________________________________________________ 
Printed Name of Research Participant (child) 
  
 
______________________________________________________ 
Signature of Parent 
 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Parent 
  
 
  
______________________________________________________ 
Signature of Research Team Member Obtaining Permission 
 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Research Team Member Obtaining Permission 
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University of North Carolina at Chapel Hill 
Assent to Participate in a Research Study 
Adolescent Participants age 15-17 
Consent Form Version Date: 04/24/17 
IRB Study: 17-1044 
Title of Study: Program Evaluation of Type-1 Diabetes Clinic at Peking University People’s Hospital in 
Beijing, China 
Principal Investigator: Elizabeth Mayer-Davis 
Principal Investigator Department: Nutrition Operations 
Principal Investigator Phone number: (919) 966-7218 
Principal Investigator Email Address: mayerdav@email.unc.edu  
Co-Investigators: Wei Liu, Jennifer Lyu, Sanjay Gadi 
________________________________________________________________________ 
What are some general things you should know about research studies? 
You are being asked to take part in a research study. Your parent, or guardian, needs to give permission 
for you to be in this study. You do not have to be in this study if you don’t want to, even if your parent 
has already given permission. To join the study is voluntary. You may refuse to join, or you may 
withdraw your consent to be in the study, for any reason, without penalty. 
Research studies are designed to obtain new knowledge. This new information may help people in the 
future. You may not receive any direct benefit from being in the research study. There also may be risks 
to being in research studies.  
Details about this study are discussed below. It is important that you understand this information so that 
you can make an informed choice about being in this research study. You will be given a copy of this 
consent form. You can ask the researchers named above, or staff members who may assist them, any 
questions you have about this study at any time. 
What is the purpose of this study? 
This is a joint study lead by researchers at the University of North Carolina at Chapel Hill and Peking 
University People’s Hospital. The purpose of the project is to improve the clinical experience of patients 
with type 1 diabetes (T1D) in Beijing, China by incorporating motivational interviewing, a patient-
centered communication style, goal setting and problem solving skills training, and nutrition education. It 
is expected that these changes to the traditional diabetes care being delivered to T1D patients in Beijing 
will help them better self-manage their diabetes and have better health outcomes, specifically in regard to 
glucose control.    
You are being asked to be in the study because you have T1D and are receiving care in the clinic in which 
this study is being performed. 
Who are eligible for this study?  
Adults with T1D older than 18 years;  
Adolescents with T1D ages 15-17 years. 
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How many people will take part in this study? 
Approximately 150 people will take part in this study, including adults and adolescents with T1D. 
 
How long will your part in this study last? What will you have to do? 
Study participants will be asked to keep their monthly appointments with the Diabetes Clinic and to 
answer a series of questionnaires before and after these visits. Your medical records will be viewed to 
collect the below information, if available, from one year before your first visit to the Diabetes Clinic 
until the end of the study period in June 2018. Study questionnaires will also be administered until June 
2018. The questionnaires and their purpose are listed below. Participants will be asked to spend an extra 
10-15 minutes before and after certain visits to complete these questionnaires. 
 
Data to be collected from medical records: 
HbA1c 
Height 
Weight 
Waist and hip circumference 
Blood pressure 
Lipid profile (total cholesterol, HDL, LDL, triglycerides) 
C-peptide 
GAD antibodies 
Urine albumin 
Urine creatinine 
 
Questionnaires to be administered: 
Nutrition Knowledge and Diet Survey (2) – this questionnaire has two versions: the first version 
includes questions about your past diabetes education relating to nutrition, as well as nutrition 
knowledge; the second version includes evaluation questions regarding the nutrition brochure you 
will be given, as well as nutrition knowledge  
Diabetes Interview Satisfaction Scale (DISS) – this questionnaire will ask about your satisfaction with 
the care being provided at the Diabetes Clinic 
Diabetes Self-Management Survey (DSMQ-SR) – this questionnaire will ask about how you self-
manage your diabetes 
Intention and Motivation Survey – this questionnaire will gauge how intent and motivated you are on 
self-managing your diabetes. 
 
How will information about you be protected? 
You will be given an ID number during participation in the study. The information collected from you in 
the questionnaires and your medical records will not be connected with your name or any other 
information that identifies you. All questionnaires will be administered on an electronic tablet provided in 
the Diabetes clinic. All the information collected for study purposes will be de-identified (with the 
exception of signed consent forms). There is a minimal potential risk associated with loss of 
confidentiality of health-related information. All paper versions of forms will not contain any identifiable 
information, and will be stored in a locked file cabinet in a locked office in Peking University People’s 
Hospital. However, in the event of an unlikely data breach, all data will be unidentifiable and will not be 
stored with any personal identifiers with the exception of signed consent forms. All discussions of study 
eligibility and participation will also occur in a private setting to protect the privacy of patients and avoid 
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accidental status disclosure. Participants will not be identified in any report or publication about this study. 
 
What if you want to stop before your part in the study is complete? 
Your participation in this study is completely voluntary. You can withdraw from this study at any time 
without penalty. Whether or not you decide to participate in this study will have no influence on your 
medical treatment at Peking University People’s Hospital. 
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might affect your 
willingness to continue your participation.  
 
Will you receive anything for being in this study? 
Research is designed to benefit society by gaining new knowledge. You will not receive any monetary 
compensation for your participation in this study. You will receive the same quality of care at the 
Diabetes Clinic whether you choose to participate in the study or not. 
 
What are the possible risks or discomforts involved from being in this study? 
It will not cost you anything to be in this study. The risk for joining in this study is very minimal. The 
surveys may make you mentally tired while answering the questions. If you feel this way from taking the 
survey, you can stop at any time. The medical staff members at the Peking University People’s Hospital 
are trained to counsel and support you and your family. There may be uncommon or previously unknown 
risks. You should report any problems to the researcher.  
 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this research. If you 
have questions about the study, including complaints, concerns, or research-related injuries—which are 
unlikely—you should contact the researchers listed on the first page of this form. 
 
What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your rights and 
welfare.  If you have questions or concerns about your rights as a research subject, or if you would like to 
obtain information or offer input, you may contact the Peking University People’s Hospital Institutional 
Review Board at 010-88324526. 
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Participant’s Agreement: 
I have read the information provided above. I have asked all the questions I have at this time. I voluntarily 
agree to participate in this research study. 
  
  
______________________________________________________ 
Your signature if you agree to be in the study 
 
____________________ 
Date 
 
______________________________________________________ 
Printed name if you agree to be in the study 
  
 
  
______________________________________________________ 
Signature of Research Team Member Obtaining Assent  
 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Research Team Member Obtaining Assent 
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Appendix C: DISS, DSMP, and Intention and Motivation Questionnaires and Chinese 
Translations 
 
PID: _____________ 
 
 
Diabetes Interview Satisfaction Scale 
 
Below is a list of statements concerned with your views of the consultation today. Beside each 
statement there is a scale that ranges from 1 (‘Strongly disagree’) to 5 (‘Strongly agree’). For each 
item please circle that number that represents the extent to which you agree with the statement. 
Please answer every item and only make one choice per item. Please respond as honestly as you 
can and remember that your responses will remain confidential and will not be shown to your doctor.  
 
A. Today’s date is 
 
 
 
 
 
 
 
Time satisfaction items 
 
1. The doctor/nurse seemed 
rushed when talking to me 
 
2. The doctor/nurse gave 
directions too fast 
 
3. The doctor/nurse was too 
abrupt with questions 
 
4. The doctor/nurse did not  
spend enough time with me 
 
5. The doctor/nurse looked into 
all the problems I mentioned 
 
 
Affective satisfaction items 
 
6. The doctor/nurse gave me 
      a chance  to say what was  
      on my mind 
 
7. I was satisfied by the way  
the doctor/nurse reached 
the decision about my  
treatment 
 
8. I felt really understood by  
my doctor/nurse 
 
9. The doctor/nurse gave me a 
thorough interview 
 
10. I felt free to talk about my 
private thoughts 
   1              2            3      4        5 
   1              2            3      4        5 
   1              2                      3      4        5 
   1              2            3      4        5 
   1              2            3      4        5 
Strongly       Disagree       Uncertain       Agree    Strongly    
disagree                  agree 
     
   1              2            3      4        5 
   1              2            3      4        5 
   1              2            3      4        5 
   1              2            3      4        5 
   1              2            3      4        5 
Month      Day         Year 
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糖尿病门诊满意度调查问卷 
 
以下调查是关于您对今天门诊就诊的满意程度。每一个陈述后您都可以按照自己的实际感受选择从“1”
到“5”的数字代表“强烈不同意”至“强烈同意”。请针对每一个陈述做出回答，并记住只勾选一个选项。
请您按照自己的实际感受回答即可，您的医生并不会知道您做出的选择。  
 
 
A. 今天的日期是  
 
 
 
 
 
 
时间满意度调查  
 
1. 医生/护士看上去十分匆忙， 
没有时间听我陈述 
 
2. 医生/护士给予建议的过程 
过于急促 
 
3. 医生/护士的提问太突然了 
 
 
4. 医生/护士没有给予我足够 
的时间 
 
5. 医生/护士关注了我提出的 
每个问题 
 
 
 
情感满意度调查  
6. 医生/护士给了我 
      时间说出自己的想法 
 
7. 我对于医生/护士对我疾病的 
诊疗计划非常满意 
 
 
8. 我感觉医生/护士理解了我 
的想法 
 
9. 我感到医生/护士给予了我 
系统性的彻底诊疗 
 
10. 我感觉可以很自由的谈论 
自己的感受 
 
 
 
   1              2            3      4        5 
   1              2            3      4        5 
   1              2                      3      4        5 
   1              2            3      4        5 
   1              2            3      4        5 
 强烈                                        强烈 
不同意         不同意      不确定 同意    同意 
同      
   1              2            3      4        5 
   1              2            3      4        5 
   1              2            3      4        5 
   1              2            3      4        5 
   1              2            3      4        5 
       年                              月                 日  
   PID: _____________ 
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Diabetes	Self-Management	Survey	(DSMP-SR),	Participant	
These are questions about how you have usually taken care of your diabetes since your last visit. Please answer each question 
as truthfully as you can. 
 
 
1. Today’s date is                 
    .......................................................................................................................................................  ............................      
  
2. In the past 3 months, how often have you gotten exercise such as running, bike riding, swimming, skating, or playing 
team sports for at least 20 minutes?  
 □ More than three times per week  
 □ 2 – 3 times per week  
 □ Once a month  
 □ Less than once per month  
 
3. In the past 3 months, if you got more exercise than usual, or planned to get more exercise than usual, what did you 
usually do about the meal plan or insulin?  
  □ I exercise so consistently that adjustments are unnecessary  
  □ I always eat more or give less insulin  
 □ I frequently eat more or give less insulin (2-3 times per week)  
 □ Sometimes I eat more or give less insulin (once a week)  
 □ Occasionally I eat more or give less insulin (few times a month)  
 □ I eat less than usual or give more insulin  
 □ I never adjust my eating or insulin  
 
4. In the past 3 months, if you got less exercise than usual, or if you planned to get less exercise, what did you usually do 
about the meal plan or insulin?  
 □ I exercise so consistently that adjustments are unnecessary  
  □ I always eat less or give more insulin  
 □ I frequently eat less or give more insulin (2-3 times per week) 
 □ Sometimes I eat less or give more insulin (once a week) 
 □ Occasionally I eat less or give more insulin (few times a month) 
  □ I eat more than usual or give less insulin  
  □ I never adjust my eating or insulin  
5. Do you keep something handy in case your sugar gets too low?  For example, when you are at school or at a ball 
game, or in the car and your sugar gets too low, do you have something handy to eat?  
□ Yes  
□ No   
 
 
Month      Day         Year 
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6. If you think you are having a low blood sugar, how often do you check your blood sugar before treating?  
□ I have not had a low blood sugar in past 3 months  
□ I always check before treating a low blood sugar  
 □ I usually check before treating a low blood sugar (more than half the time) 
□ Sometimes I check before treating a low blood sugar (about half the time) 
□ I check infrequently before treating a low blood sugar (less than half the time) 
□ I never check before treating a low blood sugar  
 
7. People take care of low blood sugars in many different ways.  What did you usually do to treat your low blood 
sugars in the past 3 months?  
□ I have not had a low blood sugar in the past 3 months  
□  I am careful to quickly take the right amount of carbs and check my blood sugar after 10 minutes  
□  I take the right amount of carbs but I do not check blood my sugar afterwards  
□ I take some carbs without thinking about how much I need  
□ I keep taking carbs until I feel better  
□ I ignore symptoms until there's a better time to treat my low blood sugar  
 
8. Do you wear or carry any kind of diabetic identification, like a card or bracelet? 
□ I wear a necklace, bracelet, charm, or have a tattoo  
□ I carry an ID card in my wallet or purse  
□ I don't wear or carry diabetic identification  
 
8a.  In the past 3 months, did you usually count carbs, measure or weigh food, or use exchanges  to figure out 
how  much insulin to take?   
□ I use carb counting (or exchange list) and measure food or read labels if needed to decide how much insulin to take  
□ I know carb amounts well enough so that I can take the right amount of insulin  
□ I eat about the same amounts of food each meal, so I can take the set insulin dose or use a sliding scale  
□ I just take a set insulin dose or use a sliding scale, regardless of what I eat  
  
8b. In the past 3 months, did you usually count carbs, measure or weigh food, or use exchanges to figure out how 
much to eat?  
□ I use carb counting (or exchange list) as a guide and either measure food or read labels  
□ I use carb counting (or exchange list) as a guide, but I know my meal plan well enough so that I can eat the right 
amounts without measuring or reading labels  
□ I eat about the same amounts of food each meal, but I don’t use carb counting, measuring or an exchange list  
□ I eat the amount I am hungry for and don’t use carb counting, measuring, or exchange lists  
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9.  In the past 3 months, how often have you eaten "fast foods" or "junk foods" such as sweets, cookies, cakes, 
ice cream, chips, pizza, french fries, hot dogs, or others?  
 
□ Occasionally (few times a month or less) 
□ Sometimes (once a week) 
□ Frequently (2-3 times per week) 
□ Almost always (4 or more times per week) 
□ Everyday  
 
10.  In the past 3 months, how often have you eaten more than what was planned?  
 
□ Never or hardly ever (1-2 times in the last 3 months)  
□ Seldom (once a month) 
□ Occasionally (few times each month) 
□ Frequently (2-3 times per week) 
□ Almost daily (4 or more times per week) 
 
11.  In the past 3 months, before you ate more than usual, did you make any insulin changes?   
□ I give MORE insulin when I eat more  
□ I give LESS insulin when I eat more  
□ I do not change my insulin  
 
12. In the past 3 months, how often have you eaten less than what was planned?  
 
□ Never or hardly ever (1-2 times in the last 3 months)  
□ Seldom (once a month)  
□ Occasionally (few times each month)  
□ Frequently (2-3 times per week)  
□ Almost daily (4 or more times per week)  
 
13.  Before you eat less than usual, do you make any insulin changes?  What do you do?  
□ I give LESS insulin when I eat less  
□ I give MORE insulin when I eat less  
□ I do not adjust my insulin  
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14.  In the past 3 months, how often have you checked your blood sugar?  
□ 6 or more times daily  
□ 4 or 5 times daily  
□ 2 or 3 times daily  
□ At least once daily  
□ Less than once daily  
□ I do not check my blood sugar  
 
15.  In the past 3 months, how often did you do a blood sugar check within 30 minutes before a meal?  
□ I always check my blood sugar within 30 minutes before every meal  
□ I usually check within 30 minutes before meals (more than half the time)  
□ I sometimes check within 30 minutes before meals (about half the time)  
□ I infrequently check within 30 minutes before meals (less than half the time)  
□ I never check within 30 minutes before meals  
 
16. In the past 3 months, how often did you do a blood sugar check within 2-3 hours after a meal? 
□ I check my blood sugar within 2-3 hours after a meal 4 or more times per week  
□ I check within 2-3 hours after a meal 3 times per week  
□ I check within 2-3 hours after a meal 2 times per week  
□ I check within 2-3 hours after a meal once a week  
□ I never check within 2-3 hours after meals  
 
17.  In the past 3 months, how often did you do a blood sugar check within 2-3 hours after heavy exercise?  
□ I always check my blood sugar within 2-3 hours after exercise  
□ I check 2-3 hours after exercise more than half the time  
□ I check 2-3 hours after exercise about half the time  
□ I check 2-3 hours after exercise less than half the time  
□ I never check 2-3 hours after exercise   
 
18. In the past three months, how often have you changed either the insulin dose, diet or exercise when the blood sugars 
were running high?  
□ I made a change every time it was needed  
□I made a change when needed more than half the time  
□ I made a change when needed about half the time  
□ I made a change when needed less than half the time  
□ I never made a change when needed  
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19.  In the past 3 months, if you had two blood sugar results above 240 in a row, how often did you do a ketone test?  
□ I did not have two blood sugars in a row above 240  
□ I always checked for ketones after 2 blood sugars in a row above 240  
□ I usually checked for ketones after 2 blood sugars in a row above 240 □ I occasionally checked for ketones after 2 
blood sugars in a row above 240  
□ I never checked for ketones after 2 blood sugars in a row above 240  
 
20.  When you've been sick, how often did you do a ketone test?  
□ I always check for ketones several times a day when I am sick  
□ I always check for ketones once a day when I am sick  
□ I usually check for ketones once a day when I am sick  
□ I occasionally test for ketones when I am sick  
□ I never test for ketones when I am sick  
 
21. In the last three months, how often have you taken insulin more than 30 minutes late?  
□ Never, I always take insulin on time  
□ I have been late once a month or less  
□ I have been late once a week or less  
□ I have been late more than once a week  
 
22. In the past 3 months, how often have you taken MORE insulin than you should have?  
□ I always took the prescribed amount  
□ I took more than prescribed amount 1 -3 times  
□ I took more than prescribed amount 4 - 6 times  
□ I took more than prescribed amount 7 - 10 times  
□ I took more than prescribed amount more than 10 times  
 
23. In the past 3 months, how often have you taken LESS insulin than you should have?  
□ I always took the prescribed amount  
□ I took less than prescribed amount 1 - 3 times  
□ I took less than prescribed amount 4 - 6 times  
□ I took less than prescribed amount 7 - 10 times  
□ I took less than prescribed amount more than 10 times  
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24. In the last 3 months, how often have you missed insulin because you forgot or were too busy, or your pump 
was not working or inserted?  
□ I never missed, I always take insulin  
□ I missed once a month or less (1 - 3 times in the last 3 months)  
□ I missed once a week or less  
□ I missed more than once a week  
 
Thank you. 
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糖尿病自我管理调查 	(DSMP-SR),	受试者 	
以下问题关于您平时如何进行血糖的自我管理，请就您自上次就诊后的情况进行回
答，这份问卷并没有标准答案，您按照自己的实际情况回答即可。 
 
 
1. 今天的日期是              
    .......................................................................................................................................................  ............................       .....................  
2. 在过去 3个月中，您参加体育运动，例如骑自行车、游泳、滑冰或竞技比赛至少 20分钟的
频率如何？   
 □ 每周超过 3次  
 □ 每周 2 – 3 次 
 □ 每周 1次  
 □ 每月少于 1次  
 
3. 在过去 3个月中，如果您比平时更多的运动，或计划比平常做更多的运动，  通常如何对膳
食计划或胰岛素进行调整？  
  □ 我不怎么运动因此不用进行调整  
  □ 我总是多吃一些东西或者少打一些胰岛素  
 □我经常多吃一些东西或者少打一些胰岛素(每周 2-3 次)  
 □我有时多吃一些东西或者少打一些胰岛素 (每周 1次)  
 □我偶尔多吃一些东西或者少打一些胰岛素 (少于每月 1次)  
 □ 我少吃一些或者多打一些胰岛素  
 □ 我从不调整胰岛素或者膳食  
 
4. 在过去 3个月中，如果您比平时运动减少，或计划比平常运动减少，  通常如何对膳食计划
或胰岛素进行调整？  
       □我经常运动因此不用进行调整  
  □ 我总是少吃一些东西或者多打一些胰岛素  
 □我经常少吃一些东西或者多打一些胰岛素(每周 2-3 次)  
 □我有时少吃一些东西或者多打一些胰岛素(每周 1次)  
 □我偶尔少吃一些东西或者多打一些胰岛素(少于每月 1次)  
 □ 我多吃一些或者少打一些胰岛素  
 □ 我从不调整胰岛素或者膳食 
5. 您是否会随身携带一些食物，以备出现低血糖时使用？比方说，当您在学校里、工作单位
或户外运动时，是否会随身准备一些食物？   
□ 是  
□ 否  
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6. 当您认为自己出现低血糖的时候，在处理低血糖之前，自测血糖的频率如何？   
□ 我过去 3个月中没有低血糖  
□ 我在处理低血糖之前总会测血糖 
 □ 我在处理低血糖之前经常会测血糖（超过一半的时间） 
□ 我在处理低血糖之前有时会测血糖（约一半的时间） 
□ 我在处理低血糖之前通常不会测血糖（小于一半的时间）  
□ 我在处理低血糖之前从不会测血糖 
 
7. 人们处理低血糖的方法往往不同，从上次就诊后，您平时处理低血糖的方法是怎样的？   
□ 我过去 3个月中没有低血糖 
□  我可以快速并准确的进食适当量的碳水化合物且在 10分钟后再次测血糖  
□  我可以快速并准确的进食适当量的碳水化合物，但不会复测血糖 
□ 我持续不断地进食碳水化合物而不去考虑自己到底吃了多少  
□ 我持续不断地进食碳水化合物，直到自己感觉好转  
□ 我在找到合适的机会处理低血糖之前，会忽视低血糖的存在  
 
 
8a.  在过去的 3个月中，您是否会根据计算碳水化合物的结果调整餐时胰岛素的注射？   
□ 在需要计算决定注射多少单位胰岛素时，我会计算碳水化合物（或利用食物交换份）及阅读食
品标签  
□ 我已经熟练掌握了碳水化合物的计算方法并能够计算正确的胰岛素剂量  
□ 我每顿饭都吃固定的碳水化合物量，因此就能够保证不需要调整胰岛素剂量  
□ 我按照固定的胰岛素注射方案执行，而不会关注饮食中碳水化合物的摄入  
  
8b. 在过去的 3个月中，您是否会经常进行碳水化合物计算、称量食物重量或者利用食物交换份
计算饮食的摄入量？   
□ 我运用碳水化合物计算（或食物交换份）作为指导，并称量食物或阅读食物标签  
□ 我运用碳水化合物计算（或食物交换份）作为指导，但是我足够了解我的饮食方案因而不需要
称量食物或者阅读食物标签  
□ 我每餐都吃差不多量的食物，但我不进行碳水化合物计算、称量食物或阅读食物标签  
□ 我按照自己的饥饿程度进行，而不进行碳水化合物计算、称量食物或阅读食物标签 
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25. 过去 3个月，您吃过多少次“快餐”或“垃圾食品”，如糖果、点心、蛋糕、冰淇淋、薯
条、比萨饼、炸薯条、热狗或其他？  
 
□ 偶尔 (每月 1次或更少) 
□ 有时 (每周 1次) 
□ 经常 (每周 2-3次) 
□ 几乎总是(每周 4次或更多) 
□ 每天 
 
26. 在过去的 3个月中，您进食量超过饮食计划量的频率如何？   
 
□ 从不或几乎从不(过去 3个月中 1-2 次)  
□ 很少 (每月 1次) 
□ 偶尔 (每月几次) 
□ 经常 (每周 2-3 次) 
□ 几乎每天 (每周 4次或者更多) 
 
27.  在过去的 3个月中，如果您吃的比计划饮食量多，是否会调整胰岛素剂量？    
□ 打算多吃一些的时候我会多打一些胰岛素  
□ 打算多吃一些的时候我会少打一些胰岛素  
□ 我不会调整胰岛素 
 
28. 在过去的 3个月中，您进食量少于饮食计划量的频率如何？    
 
□ 从不或几乎从不(过去 3个月中 1-2 次)  
□ 很少 (每月 1次) 
□ 偶尔 (每月几次) 
□ 经常 (每周 2-3 次) 
□ 几乎每天 (每周 4次或者更多) 
 
29.  如果您吃的比计划饮食量少，是否会调整胰岛素剂量？    
□ 打算少吃一些的时候我会少打一些胰岛素  
□ 打算少吃一些的时候我会多打一些胰岛素  
□ 我不会调整胰岛素  
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30.  在过去 3个月中，您测血糖的频率如何？   
□ 每天 6次或更多  
□ 每天 4到 5次 
□ 每天 2到 3次 
□ 每天至少 1次  
□ 每天不足 1次  
□ 我不测血糖 
 
31.  在过去 3个月中，您在餐前 30分钟内测血糖的频率如何？   
□ 我总是会测餐前 30分钟内的血糖  
□ 我常常会测餐前 30分钟内的血糖（超过一半的时间） 
□ 我有时候会测餐前 30分钟内的血糖（约一半的时间）  
□ 我不常测餐前 30分钟内的血糖（不足一半的时间）  
□ 我从不测餐前 30分钟内的血糖 
 
32. 在过去 3个月中，您在餐后 2-3小时测血糖的频率如何？  
□ 我每周会测 4次或以上餐后 2-3小时血糖  
□ 我每周会测 3次餐后 2-3小时血糖  
□ 我每周会测 2次餐后 2-3小时血糖   
□ 我每周会测 1次餐后 2-3小时血糖   
□ 我从不测餐后 2-3小时血糖   
 
 
33.  在过去 3个月中，您在剧烈运动后 2-3小时内测血糖的频率如何？?  
□ 我总是在剧烈运动后 2-3小时内测血糖  
□ 超过一半的时间里，我会在剧烈运动后 2-3小时内测血糖  
□ 约一半时间里，我会在剧烈运动后 2-3小时内测血糖 
□ 不到一半的时间里，我会在剧烈运动后 2-3小时内测血糖  
□ 我从不在剧烈运动后 2-3小时内测血糖 
 
34. 在过去 3个月中，当血糖较高时，您改变胰岛素剂量、饮食或者运动的频率如何？   
□ 只要有需要，我就会做出改变  
□ 当有需要时，超过一半的时间我会做出改变  
□ 当有需要时，约一半的时间我会做出改变 
□ 当有需要时，不足一半的时间我会做出改变 
□  我从不会在有需要时做出改变 
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35. 在过去 3个月中，如果您两次测血糖均＞14mmol/L，您测酮体的频率如何？  
□ 我没有两次血糖＞14mmol/L  
□ 当两次测血糖＞14mmol/L 时，我总是会测血酮体  
□ 当两次测血糖＞14mmol/L 时，我常常会测血酮体 
□ 当两次测血糖＞14mmol/L 时，我有时会测血酮体 
□ 当两次测血糖＞14mmol/L 时，我从不会测血酮体 
 
36. 当您生病的时候，测酮体的频率如何？  
□ 我生病的时候，总是每天都会测几次酮体  
□ 我生病的时候，总是每天都会测一次酮体  
□ 我生病的时候，通常每天会测一次酮体  
□ 我生病的时候，偶尔会测酮体  
□ 我生病的时候从不测酮体 
 
37. 自您上次就诊后，晚于应该注射胰岛素时间超过 30分钟的频率如何？   
□ 从未这样，我总是按时注射胰岛素  
□ 我每月出现一次，或少于一次这种情况  
□ 我每周出现一次，或少于一次这种情况 
□ 我每周出现这种情况超过一次 
 
38. 在过去 3个月中，您有多少次注射了比医嘱剂量多的胰岛素？   
□ 我总是注射医嘱剂量  
□ 我有比 1 -3 次注射了比医嘱剂量多的胰岛素 
□ 我有比 4 -6 次注射了比医嘱剂量多的胰岛素 
□ 我有比 7 -10次注射了比医嘱剂量多的胰岛素 
□ 我有超过 10 次注射了比医嘱剂量多的胰岛素  
 
39. 在过去 3个月中，您有多少次注射了比医嘱剂量少的胰岛素？   
□ 我总是注射医嘱剂量  
□ 我有比 1 -3 次注射了比医嘱剂量少的胰岛素 
□ 我有比 4 -6 次注射了比医嘱剂量少的胰岛素 
□ 我有比 7 -10次注射了比医嘱剂量少的胰岛素 
□ 我有超过 10 次注射了比医嘱剂量少的胰岛素 
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40. 自您上次就诊后，您因为太忙或者忘记注射胰岛素，以及胰岛素泵出现问题而未及时使用
胰岛素的频率如何？   
□ 我从未出现这些情况  
□ 我每个月出现一次或少于一次这种情况（三个月中，1~3次）  
□ 我每周出现一次或少于一次这种情况  
□ 我每周出现超过一次这种情况 
 
谢谢您！  
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Intention	and	Motivation	–	Participant		
 
A.  Today’s Date is:        
 
 
1. Please circle the number beside each question to tell us how much each statement applies to 
you, where 0 is definitely not and 10 is definitely.   
 
2. Please circle the number beside the question to tell us how much each statement applies to 
you, where 1 is not motivated at all and 10 is very motivated. 
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D
ef
in
ite
ly
 
1a. I plan to manage my diabetes.  0 1 2 3 4 5 6 7 8 9 10 
1b. I am trying to manage my diabetes.  0 1 2 3 4 5 6 7 8 9 10 
1c. It is important for me to manage my diabetes.  0 1 2 3 4 5 6 7 8 9 10 
1d. I can manage my diabetes. 0 1 2 3 4 5 6 7 8 9 10 
How motivated am I to: N
ot
 M
ot
iv
at
ed
 
A
t A
ll 
 
       
Ve
ry
 
M
ot
iv
at
ed
 
2a. check my blood sugar?  
 1 2 3 4 5 6 7 8 9 10 
2b. take my insulin?  
 1 2 3 4 5 6 7 8 9 10 
2c. eat a healthy diet?  
 1 2 3 4 5 6 7 8 9 10 
2d. get enough exercise? 
  1 2 3 4 5 6 7 8 9 10 
Month      Day         Year 
         (患者自填) 
Study ID   
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意愿和能动性---患者 		
 
B.  今天的日期是:        
 
 
3. 请在下述表格中圈出这些论述与你的体会相符合的程度。0代表完全不符合，10代表完全符合。 
 
 
2.  请在下述表格中圈出这些论述与你的体会相符合的程度。0代表完全没有受到鼓舞，10代表十分
受到鼓舞。 
 
 
 
 
 
 
 
 
 
 
 
 
 
完
全
不
符
合
 
 
可
能
不
符
合
 
  
也
许
 
 
差
不
多
 
  
完
全
符
合
 
1a. 我计划好好控制糖尿病。 0 1 2 3 4 5 6 7 8 9 10 
1b. 我正在尝试控制糖尿病。 0 1 2 3 4 5 6 7 8 9 10 
1c. 控制糖尿病对我而言十分重要。 0 1 2 3 4 5 6 7 8 9 10 
1d. 我能控制好糖尿病。 0 1 2 3 4 5 6 7 8 9 10 
我受到的鼓舞：  完
全
没
有
受
到
 
 
       
十
分
受
到
 
2a. 测血糖?  
 
1 2 3 4 5 6 7 8 9 10 
2b. 注射胰岛素?  
 
1 2 3 4 5 6 7 8 9 10 
2c. 健康饮食?  
 
1 2 3 4 5 6 7 8 9 10 
2d. 足够的体育锻炼? 
  
1 2 3 4 5 6 7 8 9 10 
        年                                    月                     日  
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Appendix D: New Clinical Consultation Protocol and Chinese Translation 
Consultation 1 
(15-20 minutes)  
 
1A. Raise the Issue_____________________________________________________ 
Patient walks in and exchanges greetings with physician. 
 
Physician: “Hello! What brings you in today?” 
 
Patient conveys first concern 
 
Physician:  “Okay, we can talk about [concern 1]. Are there any other concerns you would 
like to talk about today?” 
 
Patient conveys other concerns (2, 3, 4, etc.) until all concerns have surfaced.  After 
each concern is voiced, summarize all concerns voiced so far. 
 
OR 
 
Patient does not convey any other concerns.   
 
Physician: “Just to be sure I understand correctly, [concern 1] and/or [concern 2]?” 
Patient confirms to physician all concerns*.  
Physician negotiates patient’s chief concerns with own clinical judgment to focus on the topic of that 
day’s visit 
   
1B. Development of a Shared Agenda________________________________________ 
Using clinical judgment (i.e. lab measurements, including height, weight, waist circumference, hip 
circumference, blood pressure, HbA1c, lipid profile, c-peptide, GAD antibodies, urine albumin, and 
urine creatinine), doctor decides whether there’s something else that’s important to discuss or 
whether patient concerns already raised take priority. 
  
IF new topic: “[Provide context: reference additional observation made by physician related 
to patient’s health]. I think it’s important that we add [new concern] to our discussion. [Brief 
explanation of why it’s important]. Would that be ok?  
  
IF no new topic: Physician deems which concern is most important to address first and 
explains why to patient.  
  
Physician decides the agenda, negotiating patient’s concerns and clinical knowledge. 
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“I would like to discuss [concerns 1-2] and [new concern] together. They’re pretty closely 
related. Is that okay?” 
  
OR 
  
“I want to make sure we have time for [new concern], so how about we discuss that first? 
We’ll certainly still have time to discuss [concerns 1-2] afterward.” 
  
OR 
  
“Okay, sounds good. Let’s start with [concerns 1 and/or 2].” 
  
Establish baseline of information with a broad question. Allow patient to finish answering the 
question before referencing PP information and setting a goal to address the patient’s specific 
concerns  
 
Physician: “Could you tell me what you understand about [concern] and what are you 
currently doing to manage this concern?” 
  
Patient responds 
  
Physician: “Okay, go on.” 
  
Patient elaborates, providing full picture. 
 
Responses affirming the patient’s concerns should focus on their understanding and ability, and the 
importance of this topic. 
  
➢ Summarize nutrition-specific concern 
 
Physician: “Well, it’s clear to me how [nutrition-specific concern] is making [self 
management technique] difficult for you.” 
 
➢ Empathize with patient’s struggles 
 
Physician: “I can also see that you want to feel more comfortable with what you 
choose to eat, and still stay in control of your blood sugar.” 
 
➢ Direct conversation towards better self-management while still involving patient as a key 
player. Example: 
  
Physician: “Let’s discuss how we might work on this together.” 
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1C. Addressing Concern, Part 1: Educational Approach_________________________ 
 
First, physician communicates information on causes and effects of the [concern of focus] to the 
patient. Physician reminds patient to feel free to ask questions throughout the following educational 
component of the clinical consultation. 
 
Second, physician introduces the Chinese-adapted version of the U.S. diabetes educational 
material, “Understanding Diabetes” (Pink Panther Book) to the patient. Physician points to specific 
chapters in the book that are related to the patient’s specific concern. The purpose of the 
“Understanding Diabetes” book is to provide the patient a physical, illustrative, and interactive 
resource.  
 
Physician:  “I have this book which is commonly used for T1D education. There’s a lot of 
useful information in here about T1D self-management, including information about insulin 
and how to use it, diet and physical activity, and what to do on a day when you're not feeling 
well. I’d like to specifically show you [chapter x] that relates to your specific need. Would it 
be okay for me to share this book with you?” 
 
In the next section, physician will reference nutrition materials related to the patient’s concerns and 
discuss the patient’s personal dietary practices that have an influence on his/her T1D management.  
 
1D. Sharing of Nutrition-Specific Material and Illustrations: What is a healthy diet?____ 
Physician next transitions consultation to specifically discuss patient’s nutrition and dietary 
practices. 
 
Physician: “In addition to what we have been discussing so far in terms of your diabetes 
management, let’s do a brief overview of what a healthy diet looks like and why good 
nutrition is important for managing your diabetes.”  
 
Physician shows patient Chinese ‘Food Guide Pagoda,’ developed by the Chinese Nutrition 
Society, a diagram that demonstrates the 5 Chinese food groups [this illustration is found in the 
Nutrition Brochure that is part of the Nutrition consultation]. Physician explains content of this 
illustration.  
 
Physician shows patient ‘Healthy Plate Suitable for Chinese Diet’ developed by the Chinese 
Diabetes Society, a diagram that demonstrates a recommended healthy plate of food [this 
illustration is found in the Nutrition Brochure that is part of the Nutrition consultation]. Physician 
explains content of this illustration.  
 
While physician is explaining the illustrations above, physician will briefly define what a 
carbohydrate is and their importance to blood glucose level. 
 
Physician: “Carbohydrates are a major building block of food and an importance source of 
energy for your body. Your body breaks them down into sugars. In that way, carbohydrates 
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are directly linked to your blood sugar or blood glucose. This is why it is so important to 
keep a close eye on your carbohydrate intake. Examples of foods that are almost 
completely made up of carbohydrates include rice, bread, noodles, and steamed buns.”  
 
Physician should also stress that other foods, such as fruit contain carbohydrates.  
Physician introduces the idea and importance of matching food-insulin, but explains that because of 
limited time, not until Consultation 2 will the physician explain in further detail the concept of carb 
counting, an accurate method for matching food and insulin.  
 
Physician: “Great, now I’d like for us to go back to your original concern and keeping what 
we just discussed in mind, from the PP book and what makes up a healthy diet, to set a goal 
together that will best address your [concern]”  
 
1E. Addressing Concern, Part 2: Goal Setting and Problem Solving Skills Training____ 
Physician discusses a goal with the patient that is specific to the patient’s needs. Physician explains 
the goal and what components in relation to the patient’s treatment are involved in this goal.  
 
Physician: “Great, now I’d like for us to set a goal to help us address your [concern].” 
 
Physician introduces Problem-Solving Skills Training: Bright IDEAS method 
 
Physician: “We’re going to be using the ‘Bright IDEAS’ framework to approach our goal 
setting.” 
 
Physician gives patient diagrammatic sheet containing visual aids for the Bright IDEAS framework, 
the Wheel of Change, and the Decisional Balance Scales of Willingness and Confidence. This 
diagrammatic sheet will over tangible complement to ideas to be discussed. 
 
Physician shows patient Bright IDEAS diagram and begins discussing the 5 steps to the Bright 
IDEAS framework. 
 
➢ IDENTIFY what patient wants to change. 
 
Physician: “We can start by identifying what you want to change. I’d like to ask you 
some questions about the context surrounding [concern] to help us create a 
personalized goal.” 
          
Where does the problem happen? 
When does the problem happen?    
Who else is involved as part of the problem?    
Why does the problem happen? 
How do you feel and act when it happens? 
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Physician: “Great, now that we’ve considered what you want to change, I’d like to show 
you the Wheel of Change. This basically helps us figure out how ready you are to make 
a change.” 
 
Physician shows patient Wheel of Change and explains the 5 different stages. 
 
1. “I messed up but I want to get my diabetes under control again” 
2. “Maybe I want to change, but not right now.” 
3. “I’m ready to make a change.” 
4. “I am doing something to change.” 
5. “I’m doing things differently to control my diabetes.” 
 
Physician: “So, in consideration of this, where do you think you are in terms of your 
readiness to change?” 
 
Patient responds. 
 
Physician shows patient Decisional Balance Scales and draws attention to scale measuring 
Willingness to Change. 
 
Physician: “Next, I want to get a sense of how you feel about this change. Could you 
tell me, on a scale of 1-10, how willing are you to make [change].” 
 
Patient responds 
 
Physician: “So it sounds to me that [comment on number]. Is that correct? Could you 
tell me why you feel that way?” 
 
Patient responds 
 
Physician: “I see, [discusses more as appropriate].  
 
IF patient is not willing to make a change: Physician will ask why the patient is reluctant to 
make change and tries to better understand the barriers that the patient sees. Physician will 
then try to adjust goal to better match the patient’s comfort level.  
 
➢ DEFINE choices for how to make the change. 
 
Physician: “Ok, given this information, let’s brainstorm some possible goals to approach 
this change. Let’s start by defining some choices. We’re not going to evaluate our 
choices yet, but we will prioritize choices as our next step. Here are some possible goals 
we can set.”  
 
Physician presents ideas for goals. 
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➢ EVALUATE choices and discusses with patient. 
       
Physician: “So, among these choices, this is what I would suggest [and explains why]. 
What do you think of this?” 
  
IF patient responds affirmatively, proceed. 
 
IF patient disagrees, physician asks why patient feels this way. Using this information, 
physician either advocates for original suggestion or makes  suggestion for new goal. 
 
Physician shows patient Decisional Balance Scales and draws attention to scale measuring 
Confidence in Changing. 
 
Physician: “Let’s now reflect on how you feel about our progress so far. Can you tell 
me, on a scale of 1-10, how confident are you in your ability to make a change?” 
 
Patient responds. 
 
Physician: “So it sounds to me that [comment on number]. Is that correct? Could you 
tell me why you feel that way?” 
 
Patient responds 
 
Physician: “Okay, [discusses more as appropriate]. 
 
➢ ACT out the choice. 
   
Physician asks further questions to flesh out goal. 
         
How exactly do you envision this goal happening? 
Who is going to be involved? Who is going to help you? 
Where are you going to practice [goal]? 
When are you going to practice [goal]? 
 
➢ SEE if what patient did worked and what to do next.  
 
Physician: “Great! So here’s what I want you to work on: [summarize goal with 
additional clinical recommendations]. At your follow-up appointment, I will check with you 
on the progress of your goal and see if we will need to make any adjustments.” 
Physician ends consultation. 
 
After this first consultation, physician will schedule a 1-month follow up appointment with patient to 
complete Consultation Two.  
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Consultation 2 
(15-20 minutes) 
 
2A. Review Goal, Identify Barriers, and Problem Solve___________________________ 
 
Physician: “Hi, nice to see you today. Before we talk about any possible new concerns, I would like 
to discuss the progress of the goal we made for you in our first meeting together. Would that be 
okay?” 
 
Patient responds 
 
Physician: “So how have things been going with your goal since the last time we spoke?” 
 
There are several scenarios that could play out: 
1. Participant may not have attempted any changes. 
2. Participant might have attempted changes but not been successful. 
3. Participant might have attempted changes and been successful. 
 
In all cases, the aim here is to use MI techniques to continue to move in the direction of change, 
either in terms of building motivation or supporting behavioral change. Roll with resistance as 
necessary. 
 
Ask open-ended questions about any changes or attempted changes. 
● What changes did you try to make this week? What was it like? 
● What parts of the Bright IDEAS problem-solving worked or didn’t work? 
● What barriers did you face? How did you attempt to overcome them? 
 
Physician: “It sounds like to me that [summarizes progress and experience with old goal].” 
 
2B. Introduction of Possible New Concerns___________________________________ 
 
Physician: “So how are things for you now? What has changed? Are there any new concerns you 
would like to talk about?” 
 
IF patient has new concerns or physician notices new concern, physician prioritizes concerns using 
clinical judgment and refers to Consultation One script. 
 
IF patient has no new concerns,  
 
Physician summarizes what patient should continue to work on in relation to previous goal 
and asks if patient has any last questions. Physician addresses questions and states that at 
next follow-up appointment, further progress of the goal will be made. 
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2C. Nutrition-Centered Care: Review of ‘What is a Carbohydrate?’_________________ 
 
This training will be a standard protocol taught by physicians at the clinic to all patients with T1D. 
For patients who already master carbohydrate counting as part of their self-management routine, 
physician will ensure that patient has a clear understanding of the concept and may provide 
education on the impact of protein and fat on glycemic excursions (from ADA statement).  
 
Physician: “Now, I want to introduce to you a new way to think about your diet to help you 
eat healthy and keep your blood sugar at a healthy level. At our last consultation together, 
we discussed that the goal of nutrition for T1D is to make sure you have a healthy diet 
overall and that the food you eat matches the insulin you take, and that is what will keep 
your blood glucose under control.” 
 
Physician reviews with patient what a carbohydrate is and their importance to blood glucose level. 
 
Physician: “Carbohydrates are a major building block of food and an importance source of 
energy for your body. Your body breaks them down into sugars. In that way, carbohydrates 
are directly linked to your blood sugar or blood glucose. This is why it is so important to 
keep a close eye on your carbohydrate intake. Examples of foods that are almost 
completely made up of carbohydrates include rice, bread, noodles, and steamed buns.”  
 
Note: Physician should also emphasize that other food groups, such as fruits, contain carbs as well.  
 
2D. Carbohydrate Counting Education (CCE)__________________________________ 
 
Physician begins formal Carbohydrate Counting Education (CCE) and relates this CCE specific to 
the patient’s meal plan, educating patient on adjusting insulin dosage based on carbohydrate 
intake.  
 
2E. Identifying Components of Patient’s Meal Plan and Challenges to Adherence_____ 
 
Physician first asks patient if he/she is currently following a strict meal-plan? If so, refer to this meal 
plan for the rest of the consultation to keep the discussion specific to the patient’s dietary practices. 
Possible questions physicians may ask patient:  
 
● How similar is your current diet in comparison to this ‘Healthy Plate’ illustration?  
● What part of this plate would you say makes up a majority of your diet?   
● Is it hard for you to eat a healthy diet in your day-to-day life?  
● Are you currently following a meal-plan? If so, who helped you formulate this meal-plan?  
● Are you adhering to your meal plan? If not, what makes sticking with this meal plan 
challenging for you? Or, what makes eating a healthy diet difficult for you?  
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2F. Addressing Patient’s Dietary Challenges: Setting Nutrition-Specific Goals________ 
 
After physician and patient discuss the patient’s personal dietary practices and possible challenges 
being faced, physician will work with patient to set a new goal centered around meal planning. 
Physician will use the ‘Summarize, Empathize, Direct” method utilized in the First Consultation.  
  
➢ Summarize nutrition-specific concern 
 
Physician: “Well, it’s clear to me how [nutrition-specific concern] is making [self 
management technique] difficult for you.” 
 
➢ Empathize with patient’s struggles 
 
Physician: “I can also see that you want to feel more comfortable with what you 
choose to eat, and still stay in control of your blood sugar.” 
 
➢ Direct conversation towards better self-management while still involving patient as a key 
player. Example: 
  
Physician: “Let’s discuss how we might work on this together.” 
 
2G. Addressing Nutrition-Specific Concern: Goal Setting and Bright IDEAS Method___ 
 
Physician: “We’re going to be using the ‘Bright IDEAS’ framework to approach our goal setting.” 
 
Physician gives patient diagrammatic sheet containing visual aids for the Bright IDEAS framework, 
the Wheel of Change, and the Decisional Balance Scales of Willingness and Confidence. This 
diagrammatic sheet will over tangible complement to ideas to be discussed. 
 
Physician shows patient Bright IDEAS diagram and begins discussing the 5 steps to the Bright 
IDEAS framework. 
 
➢ IDENTIFY what patient wants to change. 
 
Physician: “We can start by identifying what you want to change. I’d like to ask you 
some questions about the context surrounding [concern] to help us create a 
personalized goal.” 
          
Where does the problem happen? 
When does the problem happen?    
Who else is involved as part of the problem?    
Why does the problem happen? 
How do you feel and act when it happens? 
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Physician: “Great, now that we’ve considered what you want to change, I’d like to show 
you the Wheel of Change. This basically helps us figure out how ready you are to make 
a change.” 
 
Physician shows patient Wheel of Change and explains the 5 different stages. 
 
1. “I messed up but I want to get my diabetes under control again” 
2. “Maybe I want to change, but not right now.” 
3. “I’m ready to make a change.” 
4. “I am doing something to change.” 
5. “I’m doing things differently to control my diabetes.” 
 
Physician: “So, in consideration of this, where do you think you are in terms of your 
readiness to change?” 
 
Patient responds. 
 
Physician shows patient Decisional Balance Scales and draws attention to scale measuring 
Willingness to Change. 
 
Physician: “Next, I want to get a sense of how you feel about this change. Could you 
tell me, on a scale of 1-10, how willing are you to make [change].” 
 
Patient responds 
 
Physician: “So it sounds to me that [comment on number]. Is that correct? Could you 
tell me why you feel that way?” 
 
Patient responds 
 
Physician: “I see, [discusses more as appropriate].  
 
IF patient is not willing to make a change: Physician will ask why the patient is reluctant to 
make change and tries to better understand the barriers that the patient sees. Physician will 
then try to adjust goal to better match the patient’s comfort level.  
 
➢ DEFINE choices for how to make the change. 
 
Physician: “Ok, given this information, let’s brainstorm some possible goals to approach 
this change. Let’s start by defining some choices. We’re not going to evaluate our 
choices yet, but we will prioritize choices as our next step. Here are some possible goals 
we can set.”  
 
Physician presents ideas for goals. 
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➢ EVALUATE choices and discusses with patient. 
       
Physician: “So, among these choices, this is what I would suggest [and explains why]. 
What do you think of this?” 
  
IF patient responds affirmatively, proceed. 
 
IF patient disagrees, physician asks why patient feels this way. Using this information, 
physician either advocates for original suggestion or makes  suggestion for new goal. 
 
Physician shows patient Decisional Balance Scales and draws attention to scale measuring 
Confidence in Changing. 
 
Physician: “Let’s now reflect on how you feel about our progress so far. Can you tell 
me, on a scale of 1-10, how confident are you in your ability to make a change?” 
 
Patient responds. 
 
Physician: “So it sounds to me that [comment on number]. Is that correct? Could you 
tell me why you feel that way?” 
 
Patient responds 
 
Physician: “Okay, [discusses more as appropriate]. 
 
➢ ACT out the choice. 
   
Physician asks further questions to flesh out goal. 
         
How exactly do you envision this goal happening? 
Who is going to be involved? Who is going to help you? 
Where are you going to practice [goal]? 
When are you going to practice [goal]? 
 
➢ SEE if what patient did worked and what to do next.  
 
Physician: “Great! So here’s what I want you to work on: [summarize goal with 
additional clinical recommendations]. At your follow-up appointment, I will check with you 
on the progress of your goal(s) and see if we will need to make any adjustments.” 
Physician ends consultation. 
 
After this second consultation, physician will schedule another 1-month follow up appointment with 
patient to complete the next consultation, Consultation 3 (and Beyond).  
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Consultation 3 and Beyond 
(15-20 minutes)  
 
3A. Review Goal, Identify Barriers, and Problem Solve___________________________ 
 
Physician: “Hi, nice to see you today. Before we talk about any possible new concerns, I would like 
to discuss the progress of the goals we’ve made for you in our first and second meeting together. 
Would that be okay?” 
 
Patient responds 
 
Physician: “So how have things been going with your [patient’s specific goals, including initial goal 
from first consultation and nutrition-specific goal from second consultation] since the last time we 
spoke?” 
 
There are several scenarios that could play out: 
1. Participant may not have attempted any changes. 
2. Participant might have attempted changes but not been successful. 
3. Participant might have attempted changes and been successful. 
 
In all cases, the aim here is to use MI techniques to continue to move in the direction of change, 
either in terms of building motivation or supporting behavioral change. Roll with resistance as 
necessary. 
 
Ask open-ended questions about any changes or attempted changes. 
● What changes did you try to make this week? What was it like? 
● What parts of the Bright IDEAS problem-solving worked or didn’t work? 
● What barriers did you face? How did you attempt to overcome them? 
 
Physician: “It sounds like to me that [summarizes progress and experience with previous goals].” 
 
3B. Introduction of Possible New Concerns___________________________________ 
 
Physician: “So how are things for you now? What has changed? Are there any new concerns you 
would like to talk about? ” 
 
IF patient has new concerns or physician notices new concern, physician prioritizes concerns using 
clinical judgment and refers to Goal Setting/Problem Solving Skills Training. 
 
 
After physician and patient discuss the patient’s old and new concerns, physician will work with 
patient to revise or set a new goal. Physician will use the ‘Summarize, Empathize, Direct” method 
utilized in the First Consultation.  
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➢ Summarize nutrition-specific concern 
 
Physician: “Well, it’s clear to me how [nutrition-specific concern] is making [self 
management technique] difficult for you.” 
 
➢ Empathize with patient’s struggles 
 
Physician: “I can also see that you want to feel more comfortable with what you 
choose to eat, and still stay in control of your blood sugar.” 
 
➢ Direct conversation towards better self-management while still involving patient as a key 
player. Example: 
  
Physician: “Let’s discuss how we might work on this together.” 
 
Physician: “We’re going to be using the ‘Bright IDEAS’ framework to approach our goal setting.” 
 
Physician gives patient diagrammatic sheet containing visual aids for the Bright IDEAS framework, 
the Wheel of Change, and the Decisional Balance Scales of Willingness and Confidence. This 
diagrammatic sheet will over tangible complement to ideas to be discussed. 
 
Physician shows patient Bright IDEAS diagram and begins discussing the 5 steps to the Bright 
IDEAS framework. 
 
➢ IDENTIFY what patient wants to change. 
 
Physician: “We can start by identifying what you want to change. I’d like to ask you 
some questions about the context surrounding [concern] to help us create a 
personalized goal.” 
          
Where does the problem happen? 
When does the problem happen?    
Who else is involved as part of the problem?    
Why does the problem happen? 
How do you feel and act when it happens? 
 
Physician: “Great, now that we’ve considered what you want to change, I’d like to show 
you the Wheel of Change. This basically helps us figure out how ready you are to make 
a change.” 
 
Physician shows patient Wheel of Change and explains the 5 different stages. 
 
6. “I messed up but I want to get my diabetes under control again” 
7. “Maybe I want to change, but not right now.” 
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8. “I’m ready to make a change.” 
9. “I am doing something to change.” 
10. “I’m doing things differently to control my diabetes.” 
 
Physician: “So, in consideration of this, where do you think you are in terms of your 
readiness to change?” 
 
Patient responds. 
 
Physician shows patient Decisional Balance Scales and draws attention to scale measuring 
Willingness to Change. 
 
Physician: “Next, I want to get a sense of how you feel about this change. Could you 
tell me, on a scale of 1-10, how willing are you to make [change].” 
 
Patient responds 
 
Physician: “So it sounds to me that [comment on number]. Is that correct? Could you 
tell me why you feel that way?” 
 
Patient responds 
 
Physician: “I see, [discusses more as appropriate].  
 
If patient is not willing to make a change: Physician will ask why the patient is reluctant to 
make change and tries to better understand the barriers that the patient sees. Physician will 
then try to adjust goal to better match the patient’s comfort level.  
 
➢ DEFINE choices for how to make the change. 
 
Physician: “Ok, given this information, let’s brainstorm some possible goals to approach 
this change. Let’s start by defining some choices. We’re not going to evaluate our 
choices yet, but we will prioritize choices as our next step. Here are some possible goals 
we can set.”  
 
Physician presents ideas for goals. 
 
➢ EVALUATE choices and discusses with patient. 
       
Physician: “So, among these choices, this is what I would suggest [and explains why]. 
What do you think of this?” 
  
IF patient responds affirmatively, proceed. 
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IF patient disagrees, physician asks why patient feels this way. Using this information, 
physician either advocates for original suggestion or makes  suggestion for new goal. 
 
Physician shows patient Decisional Balance Scales and draws attention to scale measuring 
Confidence in Changing. 
 
Physician: “Let’s now reflect on how you feel about our progress so far. Can you tell 
me, on a scale of 1-10, how confident are you in your ability to make a change?” 
 
Patient responds. 
 
Physician: “So it sounds to me that [comment on number]. Is that correct? Could you 
tell me why you feel that way?” 
 
Patient responds 
 
Physician: “Okay, [discusses more as appropriate]. 
 
➢ ACT out the choice. 
   
Physician asks further questions to flesh out goal. 
         
How exactly do you envision this goal happening? 
Who is going to be involved? Who is going to help you? 
Where are you going to practice [goal]? 
When are you going to practice [goal]? 
 
➢ SEE if what patient did worked and what to do next.  
 
Physician: “Great! So here’s what I want you to work on: [summarize goal with 
additional clinical recommendations]. At your follow-up appointment, I will check with you 
on the progress of your goal(s) and see if we will need to make any adjustments.” 
Physician ends consultation. 
 
IF patient has no new concerns,  
 
Physician summarizes what patient should continue to work on in relation to previous goal 
and asks if patient has any last questions. Physician addresses questions and states that at 
next follow-up appointment, further progress of the goals will be made.  
 
After this third consultation, physician will make clear to patient that this consultation is the last that 
will be utilized for research purposes, but that their care will continue as normal and that progress 
towards goals will continue to be checked on in future appointments at the Diabetes Clinic. 
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访视  1 
(15-20 分钟)  
 
1A. 提出问题_____________________________________________________ 
 
患者步入诊室，与医生互致问候。 
 
医生：“您好，今天为什么来就诊？” 
 
患者描述主要问题。 
 
医生：“好的，我们现在来讨论 [问题 1]，除了这个以外，您还有没有其他问题？” 
 
患者描述其他问题 （2、3、4等等），直到描述完所有问题。描述完所有问题后，略作总结。 
 
或 
 
患者没有其他问题了。   
 
医生：“您的意思就是，[问题 1] 和/或 [问题 2]，对吗？” 
患者判断医生理解的问题是否正确*.  
医生根据具体的临床情况及患者所关心的问题，设立本次访视需要解决的主要议题。   
 
1B. 共同设定目标__________________________________________________ 
根据相关临床指标（例如身高、体重、腰围、臀围、血压、HbA1c、血脂、C 肽、谷氨酸脱羧酶抗体、
尿微量白蛋白/肌酐等），医生判断是否有其他问题需要与患者讨论，以及患者所关心的问题是否解
决。 
  
如果有新的问题：“” [根据……] 我认为我们还应当进一步讨论一下 [新问题]。[简单解释原因]。 您
觉得如何？  
  
如果没有新问题：医生决定最应该先讨论的问题是什么，并简要的告知患者原因。  
  
医生结合患者实际情况，与患者协商制定本次访谈的主要目标，即主要解决的问题是什么。 
 
“我想把 [问题 1-2] 和 [新问题] 放在一起讨论，因为这几个问题所涉及的内如很相近，可以吗？” 
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或 
  
“我希望我们有足够的时间来讨论 [新问题]，那么我们先来讨论这个问题怎么样？当然我们还会留出
一些时间给 [问题 1-2]。” 
  
或 
  
“好的，我们现在就开始讨论 [问题 1-2]。” 
  
广义提问，由患者阐述目前的情况，在引出《糖尿病基础教育手册》和解决患者具体问题之前，引发
患者自己的思索。  
 
医生：“您能够谈谈，你自己对 [问题] 的理解呢？以及您目前是如何处理相关的问题的？” 
  
患者作答。 
  
医生：“很好，请继续” 
  
患者对相关问题进行具体阐述。 
 
根据患者对问题的理解、患者自身能力以及问题的重要程度，进行如下反馈。 
  
➢ 总结 营养相关的问题 
 
医生：“很显然 [营养相关问题] 给你的日常自我管理造成了不小的困难。” 
  
➢ 关注 患者遇到的困难 
 
医生：“我看到你非常希望能够在食物选择上获得更多的自由，而同时也能够维持良好的血糖控
制。” 
 
➢ 指导 引导性的语言描述，使患者感受到即使在接受教育的同时，自己仍然是占主导位
置的主体。例如： 
  
医生：“让我们看看如何一起解决这个问题。” 
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1C. 解决问题   第 1部分：  教育材料的引介______________________________________ 
首先， 医生向患者解释造成 [问题] 的原因及可能的结果，同时提醒患者在以下咨询过程中随时可以
提出问题。 
 
其次， 医生向患者介绍《糖尿病基础教育手册》，指出其中能够解决患者所关注问题的章节，告知
患者这本书很系统的对患者关注的问题做出了解答。  
 
医生：  “我这里有一本关于 1型糖尿病的教材，其中包含了很多实用的信息，比如胰岛素的应用、
营养管理、运动建议，以及比如你某天感到不适时应该如何处理等等。比如这一章节，里面就很好的
回答了你刚才提出的问题，你愿意拿这本书回去看看吗？” 
 
在下一部分中，医生将会向患者介绍与患者所提出问题相关的营养材料，并与患者讨论其本人的饮食
方案，以及其对血糖控制可能的影响。  
 
1D. 介绍营养材料，并探讨：什么是健康饮食？____________________________ 
 
这一部分主要侧重营养教育以及饮食管理。 
 
医生：“除了我们之前讨论过的这些问题，我们接下来讨论一下什么是健康饮食以及为什么健康的
饮食方案能够促进糖尿病管理。”  
 
医生向患者展示中国营养学会制定的“中国居民平衡膳食宝塔”，介绍五大类食物 [详细内容见营养
手册]。  
 
医生向患者展示中国营养学会制定的“中国居民平衡膳食餐盘”，介绍餐盘的含义以及使用方 [详细
内容见营养手册]。  
 
在患者进行上述介绍时，医生对什么是碳水化合物进行简单的定义，并阐述其对于血糖的重要影响。 
 
医生：“碳水化合物是食物的重要组成部分，是您身体的重要能量来源。您的身体会把它分解成糖。
因此，碳水化合物与您的血糖水平直接相关。这就是为什么密切关注碳水化合物摄入量如此重要的原
因。几乎完全由碳水化合物组成的食品主要包括米饭、面包、面条和馒头。”  
 
医生应当同时提出，其他食物，例如水果，同样含有碳水化合物。医生同时介绍将胰岛素剂量匹配于
所摄入食物的重要性，但同时强调，由于时间所限，碳水化合物计算等相关的具体内容将会在下一次
访视中详述。  
 
医生：“很好，那我们现在回到您最初始的问题，结合我们从《糖尿病基础教育手册》中学到的东
西以及健康饮食的内容，一起制定一个解决您所面临的 [问题] 的方法”  
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1E. 解决问题，第 2部分：目标制定以及解决问题能力的培养____________________ 
 
医生提出针对患者急切关心的问题的目标，并向患者解释这一目标的具体含义，以及其与患者所关心
的问题之间的关系。  
 
医生：“很好，现在让我们一起为您拟定一个目标，帮助您解决 [问题]。” 
 
医生引出问题解决能力训练：Bright IDEAS 方法 
 
医生： : “我们现在一起来用 ‘Bright IDEAS’ 方法来帮您设定一个目标。” 
 
医生向患者展示下面这张关于 Bright IDEAS方法的图片，顺着图片的思路，对下述讨论内容进行延
展补充。 
 
 
医生向患者详细阐述每一个步骤。. 
 
➢ 发现    患者想做出什么改变。 
 
医生： : “我们可以试着从您想改变什么开始，围绕您关注的 [问题]，我们先一起帮您看看您的问题
在哪里。” 
          
问题在什么地点出现？ 
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问题在什么时间出现？    
问题中是否还包含其他的人在内？    
问题为什么会出现？ 
问题出现的时候，你的感受如何?您通常会怎么做？ 
 
医生：“很好，我们现在已经确定好了您想做出的改变是什么，我们现在一起来看看“改变轮状
图”，这能帮助我们看看您现在处在哪个阶段。” 
 
医生向患者展示“改变轮状图”并解释 5个不同的阶段。 
 
1. “我以前血糖控制的不好，但现在我希望重新开始好好
控制血糖” 
2. “也许我想做一些改变，但并不是现在”  
3. “我已经做好准备进行改变了” 
4. “我已经在做出努力进行改变了” 
5. “我正在通过不同的努力试图改善我的血糖控制” 
 
医生： : “那么，看看这张图中所示的 5个阶段，您觉得哪个阶段最好的描述了您目前的状态呢？” 
 
患者作答。 
 
医生向患者展示“意愿平衡量表”，着重强调其中衡量对于改变的意愿强度部分。 
 
医生： :“接下来，我想知道您对这些改变的感受，请您告诉我，如果让您对自己进行[改变]的意愿强
度进行评分，1到 10分，您会给自己打几分？”  
 
患者作答。 
 
医生： :“所以说您的意愿是[对于具体分值的阐述]，对吗？您能否告诉我您为什么这样感觉？”  
 
患者作答。 
 
医生： : “我知道了，[做必要的讨论]。”  
 
如果患者不愿做出改变： 医生询问患者为什么不愿做出改变，进一步了解患者的面临的困难，医生
进一步调整需要解决的 [问题]。  
 
➢ 定义  选择如何做出改变的方法。 
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医生： :“好的，现在我们一起来想想具体应该如何做出改变。我们首先列出一些可能的选项，先不
去评价选项的优劣，这是下一步的内容，我们只简单列出可能的选项即可。这是一些我们可以选择的
选项。”  
 
医生列出可能的选项。 
 
➢ 评估  选项并和患者讨论。 
       
医生： :“在这些选项中，我比较推荐 [具体内容并解释原因]，您觉得怎么样？”  
  
如果患者同意，继续。 
 
如果患者不同意，医生询问原因。根据患者的原因，医生帮助重新做出选择或者给出新的建议。 
 
医生向患者展示“意愿平衡量表”，着重强调其中衡量对于改变的信心部分。 
 
医生： :“我们现在来看看到目前为止您的感受如何，从 1到 10，您来评价一下自己对于做出改变的
信心如何？” 
 
患者作答。 
 
医生： :“听上去 [对于具体分值的阐述]，是吗？您能否告诉我您为什么这样认为？”  
 
患者作答。 
 
医生：“我知道了，[做必要的讨论]。” 
 
➢ 行动  执行自己做出的选择。 
   
医生进一步提问，帮助目标的实现。 
         
您预想中，这个目标将怎样实现？ 
您实现目标过程中，会牵涉哪些人呢？哪些人会帮助您？ 
您将在哪里实现 [目标]？ 
您将什么时候实现 [目标]？ 
➢ 观察  如果患者确实采取了行动，接下来怎么做。  
 
医生：“太好了！现在我们已经制定好了目标 [总结目标以及相关的临床建议]。你下次就诊时，我们
将看看目标完成的如何，以及是否需要做一些调整。”医生结束访视。 
 
本次访视结束后，医生为患者预约下一次的方式时间，即访视 2。  
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访视  2 
（15-20分钟） 
 
2A. 回顾目标，发现障碍，解决问题___________________________ 
 
医生： :“您好！在我们讨论新问题之前，我想先讨论一下咱们上次设定的目标的完成情况，可以
吗？” 
 
患者作答。 
 
医生： : “从上次咱们见面后，您的目标执行的如何了？” 
 
可能出现的三种情况： 
1. 患者并没有尝试做出任何改变。 
2. 患者尝试做出改变，但没有成功。 
3. 患者尝试做出改变，并且成功。 
 
无论出现何种情况，都将继续应用激励性访谈的原则，增强患者的主观能动性，排除存在的阻力，并
促成改变的发生。 
 
对于改变或尝试进行的改变，进行开放式提问。 
● 您这周尝试了哪些改变呢？ 
● 上次咱们介绍的解决问题的 Bright IDEAS方法，您觉得哪些管用？或者哪些不管用呢？ 
● 您遇到了什么麻烦？您做出了什么努力来克服呢？ 
 
医生： : “也就是说，[总结目前的进步以及目标实现情况]。” 
 
2B. 引入可能出现的新问题___________________________________ 
 
医生： :“您最近感觉怎么样？有没有什么新的问题需要解决？” 
 
如果患者有新的问题，或者医生看到新的问题，医生总结提出这些新问题，参照访视 1的方法进行临
床评估。 
 
如果患者没有新问题。  
 
医生对患者需要如何进一步实现之前的目标做出总结和建议，并询问患者是否还有新问题。医生对新
问题进行解答，同时告诉患者下次访视时会再次评估目标的实现情况。 
 
2C. 营养治疗：进一步学习“什么是碳水化合物？”  _________________ 
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以下部分是医生对患者进行碳水化合物解释的标准流程。如果患者已经掌握了碳水化合物的计算等相
关知识，在这部分中，医生可以着重对脂肪、蛋白以及其对血糖的影响进行讲解。  
 
医生： :“现在，我们引入一些新的内容，来帮助您掌握健康饮食的信息，并获得良好的血糖控制。
我们上一次的访视中，曾经提到了对于 1型糖尿病营养治疗而言，最重要的是要学会调整胰岛素剂量
以适应血糖的波动，这样才能保证您的血糖水平稳定。”  
 
医生向患者讲解什么是碳水化合物以及其对血糖的重要意义。 
 
医生： :“碳水化合物是我们食物中的重要组成部分，同时是给我们的身体供能的重要来源。您的身
体可以将碳水化合物分解为糖，引起碳水化合物的摄入与血糖的变化直接相关，因此我们需要随时关
注碳水化合物的摄入量。基本只含有碳水化合物的食物包括米饭、面包、面条和馒头等等。”  
 
注：医生同时要提示患者其他一些食物中也含有碳水化合物，例如水果等等。  
 
2D. 计算碳水化合物_____________________________________________________ 
 
医生向患者介绍计算碳水化合物的方法，并根据患者的饮食结构，给出具体的指导以及如何调整胰岛
素剂量以配比至碳水化合物的摄入量。 
 
2E. 了解患者的膳食计划及执行过程中的困难___________________________________ 
 
医生首先询问患者目前是否正在执行严格的饮食计划？如果是，接下来的访视中围绕目前执行中的饮
食计划。医生可以向患者提问：  
 
● 您目前执行的饮食计划和我们通常所提到的“健康的饮食”之间有什么
相似之处？  
● 对照“中国居民平衡膳食餐盘”，您觉得您的饮食结构中那种食物占主
要部分？  
● 您在日常生活中，是否感到执行“健康的饮食”是困难的呢？  
● 您目前正在执行饮食计划吗？如果是，是否有人帮助您准备相应的食物
呢？  
● 您是否严格遵照您的饮食计划呢？如果不是，哪些因素阻碍了您执行饮
食计划呢？或者说，哪些因素影响您，使您感到执行健康的饮食计划十分困难呢？  
 
2F. 解决患者执行饮食计划的困难：设定营养目标_______________________________ 
当医生与患者讨论了患者目前执行的饮食计划以及其中遇到的困难之后，医生将会与患者讨论并设定
一个相应的营养目标。医生将应用类似第一次访视中“总结、强调、指引”的方法进行营养目标的制
定。  
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➢ 总结 营养相关的问题 
 
医生： :“听上去似乎 [营养相关的问题] 给您的糖尿病自我管理造成了一些困难。”  
 
➢ 强调 患者遇到的困难 
 
医生： : “我也知道您希望能够更为自由的选择食物，并同时达到良好的血糖控制。” 
 
➢ 指引 在将患者放在重要位置的同时，提出改善自我管理的方法。例如： 
  
医生： :“让我们一起来讨论一下如何达到这一目标。” 
 
2G. 解决营养相关的问题：目标制定以及 Bright IDEAS方法________________________ 
 
医生： :“我们准备接着利用 Bright IDEAS方法帮助我们一起制定一个营养相关的目标。”  
 
医生向患者展示 Bright IDEAS方法的图片，顺着图片的思路，对下述讨论内容进行延展补充。 
 
 
➢ 发现    患者想做出什么改变。 
 
医生： : “我们可以试着从您想改变什么开始，围绕您关注的 [问题]，我们先一起帮您看看您的问题
在哪里。” 
          
问题在什么地点出现？ 
问题在什么时间出现？    
问题中是否还包含其他的人在内？    
问题为什么会出现？ 
问题出现的时候，你的感受如何?您通常会怎么做？ 
 
医生：“很好，我们现在已经确定好了您想做出的改变是什么，我们现在一起来看看“改变轮状
图”，这能帮助我们看看您现在处在哪个阶段。” 
 
医生向患者展示“改变轮状图”并解释 5个不同的阶段。 
 
1.“我以前血糖控制的不好，但现在我希望重新开始好好控制血糖” 
2.“也许我想做一些改变，但并不是现在”  
3.“我已经做好准备进行改变了” 
4.“我已经在做出努力进行改变了” 
5.“我正在通过不同的努力试图改善我的血糖控制” 
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医生： : “那么，看看这张图中所示的 5个阶段，您觉得哪个阶段最好的描述了您目前的状态呢？” 
 
患者作答。 
 
医生向患者展示“意愿平衡量表”，着重强调其中衡量对于改变的意愿强度部分。 
 
医生： :“接下来，我想知道您对这些改变的感受，请您告诉我，如果让您对自己进行[改变]的意愿强
度进行评分，1到 10分，您会给自己打几分？”  
 
患者作答。 
 
医生： :“所以说您的意愿是[对于具体分值的阐述]，对吗？您能否告诉我您为什么这样感觉？”  
 
患者作答。 
 
医生： : “我知道了，[做必要的讨论]。”  
 
如果患者不愿做出改变： 医生询问患者为什么不愿做出改变，进一步了解患者的面临的困难，医生
进一步调整需要解决的 [问题]。  
 
➢ 定义  选择如何做出改变的方法。 
 
医生： :“好的，现在我们一起来想想具体应该如何做出改变。我们首先列出一些可能的选项，先不
去评价选项的优劣，这是下一步的内容，我们只简单列出可能的选项即可。这是一些我们可以选择的
选项。”  
 
医生列出可能的选项。 
 
➢ 评估  选项并和患者讨论。 
       
医生： :“在这些选项中，我比较推荐 [具体内容并解释原因]，您觉得怎么样？”  
  
如果患者同意，继续。 
 
如果患者不同意，医生询问原因。根据患者的原因，医生帮助重新做出选择或者给出新的建议。 
 
医生向患者展示“意愿平衡量表”，着重强调其中衡量对于改变的信心部分。 
 
医生： :“我们现在来看看到目前为止您的感受如何，从 1到 10，您来评价一下自己对于做出改变的
信心如何？” 
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患者作答。 
 
医生： :“听上去 [对于具体分值的阐述]，是吗？您能否告诉我您为什么这样认为？”  
 
患者作答。 
 
医生：“我知道了，[做必要的讨论]。” 
 
➢ 行动  执行自己做出的选择。 
   
医生进一步提问，帮助目标的实现。 
         
您预想中，这个目标将怎样实现？ 
您实现目标过程中，会牵涉哪些人呢？哪些人会帮助您？ 
您将在哪里实现 [目标]？ 
您将什么时候实现 [目标]？ 
 
➢ 观察  如果患者确实采取了行动，接下来怎么做。  
 
医生：“太好了！现在我们已经制定好了目标 [总结目标以及相关的临床建议]。你下次就诊时，我们
将看看目标完成的如何，以及是否需要做一些调整。”医生结束访视。 
 
本次访视结束后，医生为患者预约下一次的方式时间，即访视 3。 
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访视  3  
（15-20 分钟）   
 
3A. 回顾目标，发现障碍，解决问题___________________________ 
 
医生： :“您好！在我们讨论新问题之前，我想先讨论一下咱们第一次访视设定的目标以及营养目标
的完成情况，可以吗？” 
 
患者作答。 
 
医生： : “从上次咱们见面后，您的目标执行的如何了？” 
 
可能出现的三种情况： 
1.患者并没有尝试做出任何改变。 
2.患者尝试做出改变，但没有成功。 
3.患者尝试做出改变，并且成功。 
 
无论出现何种情况，都将继续应用激励性访谈的原则，增强患者的主观能动性，排除存在的阻力，并
促成改变的发生。 
 
对于改变或尝试进行的改变，进行开放式提问。 
● 您这周尝试了哪些改变呢？ 
● 上次咱们介绍的解决问题的 Bright IDEAS方法，您觉得哪些管用？或者哪些不管用呢？ 
● 您遇到了什么麻烦？您做出了什么努力来克服呢？ 
 
医生： : “也就是说，[总结目前的进步以及目标实现情况]。” 
 
3B. 引入可能出现的新问题__________________________________________ 
 
医生： :“您最近感觉怎么样？有没有什么新的问题需要解决？” 
 
如果患者有新的问题，或者医生看到新的问题，医生总结提出这些新问题，参照目标设定/问题解决
的方法进行临床评估。 
 
当医生和患者讨论完原有问题和新出现的问题后，医生帮助患者设定一个新的目标。具体方法参照第
一次访视中中“总结、强调、指引”的方法进行。 
 
➢ 总结 营养相关的问题 
 
医生： :“听上去似乎 [营养相关的问题] 给您的糖尿病自我管理造成了一些困难。”  
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➢ 强调 患者遇到的困难 
 
医生： : “我也知道您希望能够更为自由的选择食物，并同时达到良好的血糖控制。” 
 
➢ 指引 在将患者放在重要位置的同时，提出改善自我管理的方法。例如： 
  
医生： :“让我们一起来讨论一下如何达到这一目标。” 
 
医生： :“我们准备接着利用 Bright IDEAS方法帮助我们一起制定一个营养相关的目标。”  
 
医生向患者展示 Bright IDEAS方法的图片，顺着图片的思路，对下述讨论内容进行延展补充。 
 
 
➢ 发现    患者想做出什么改变。 
 
医生： : “我们可以试着从您想改变什么开始，围绕您关注的 [问题]，我们先一起帮您看看您的问题
在哪里。” 
          
问题在什么地点出现？ 
问题在什么时间出现？    
问题中是否还包含其他的人在内？    
问题为什么会出现？ 
问题出现的时候，你的感受如何?您通常会怎么做？ 
 
医生：“很好，我们现在已经确定好了您想做出的改变是什么，我们现在一起来看看“改变轮状
图”，这能帮助我们看看您现在处在哪个阶段。” 
 
医生向患者展示“改变轮状图”并解释 5个不同的阶段。 
 
1.“我以前血糖控制的不好，但现在我希望重新开始好好控制血糖” 
2.“也许我想做一些改变，但并不是现在”  
3.“我已经做好准备进行改变了” 
4. “我已经在做出努力进行改变了” 
5.“我正在通过不同的努力试图改善我的血糖控制” 
 
医生： : “那么，看看这张图中所示的 5个阶段，您觉得哪个阶段最好的描述了您目前的状态呢？” 
 
患者作答。 
 
医生向患者展示“意愿平衡量表”，着重强调其中衡量对于改变的意愿强度部分。 
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医生： :“接下来，我想知道您对这些改变的感受，请您告诉我，如果让您对自己进行[改变]的意愿强
度进行评分，1到 10分，您会给自己打几分？”  
 
患者作答。 
 
医生： :“所以说您的意愿是[对于具体分值的阐述]，对吗？您能否告诉我您为什么这样感觉？”  
 
患者作答。 
 
医生： : “我知道了，[做必要的讨论]。”  
 
如果患者不愿做出改变： 医生询问患者为什么不愿做出改变，进一步了解患者的面临的困难，医生
进一步调整需要解决的 [问题]。  
 
➢ 定义  选择如何做出改变的方法。 
 
医生： :“好的，现在我们一起来想想具体应该如何做出改变。我们首先列出一些可能的选项，先不
去评价选项的优劣，这是下一步的内容，我们只简单列出可能的选项即可。这是一些我们可以选择的
选项。”  
 
医生列出可能的选项。 
 
➢ 评估  选项并和患者讨论。 
       
医生： :“在这些选项中，我比较推荐 [具体内容并解释原因]，您觉得怎么样？”  
  
如果患者同意，继续。 
 
如果患者不同意，医生询问原因。根据患者的原因，医生帮助重新做出选择或者给出新的建议。 
 
医生向患者展示“意愿平衡量表”，着重强调其中衡量对于改变的信心部分。 
 
医生： :“我们现在来看看到目前为止您的感受如何，从 1到 10，您来评价一下自己对于做出改变的
信心如何？” 
 
患者作答。 
 
医生： :“听上去 [对于具体分值的阐述]，是吗？您能否告诉我您为什么这样认为？”  
 
患者作答。 
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医生：“我知道了，[做必要的讨论]。” 
 
➢ 行动  执行自己做出的选择。 
   
医生进一步提问，帮助目标的实现。 
         
您预想中，这个目标将怎样实现？ 
您实现目标过程中，会牵涉哪些人呢？哪些人会帮助您？ 
您将在哪里实现 [目标]？ 
您将什么时候实现 [目标]？ 
 
➢ 观察  如果患者确实采取了行动，接下来怎么做。  
 
医生：“太好了！现在我们已经制定好了目标 [总结目标以及相关的临床建议]。你下次就诊时，我们
将看看目标完成的如何，以及是否需要做一些调整。” 
 
如果患者没有新问题，  
 
医生总结患者需要继续努力的部分，并询问患者是否还有其他问题。医生对可能的问题简要回答，并
告知在下次访视中将会详细说明。  
 
今后的访视中，将着重根据《糖尿病基础教育手册》中出现的内容，结合患者的实际，应用 Bright 
IDEAS方法，协助患者发现问题、解决问题。 
 
 
 
